Imidazopyridazine derivatives as IL-17 modulators
Patent Information
- Application Number
- JP2023535832
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-07-02
- Filing Date
- 2021-12-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-12-06
AI Technical Summary
Existing treatments for inflammatory and autoimmune disorders do not effectively modulate IL-17 activity, and there is a lack of specific structural classes of compounds that provide metabolic stability and permeability for therapeutic applications.
Development of substituted imidazo[1,2-b]pyridazine derivatives that act as potent modulators of human IL-17 activity, exhibiting metabolic stability and permeability, as determined by microsomal and hepatocyte incubations and Caco-2 permeability assays.
The imidazo[1,2-b]pyridazine derivatives effectively treat and prevent inflammatory and autoimmune disorders by modulating IL-17 activity, offering improved metabolic stability and permeability for therapeutic use.
Smart Images

Figure 2022128584000001 
Figure 2022128584000002 
Figure 2022128584000003
Abstract
Description
[Technical Field]
[0001] This invention relates to heterocyclic compounds and their use in therapy. More specifically, this invention relates to pharmacologically active substituted imidazo[1,2-b]pyridazine derivatives. These compounds act as modulators of IL-17 activity and are therefore useful as pharmaceuticals for treating and / or preventing pathological conditions, including adverse inflammatory and autoimmune disorders. [Background technology]
[0002] IL-17A (originally named CTLA-8 and also known as IL-17) is a pro-inflammatory cytokine and an early member of the IL-17 family (Rouvier et al., J.Immunol., 1993, 150, 5445-5456). Subsequently, five further members of the family (IL-17B to IL-17F), including the most closely related IL-17F (ML-1), were identified, sharing approximately 55% amino acid sequence homology with IL-17A (Moseley et al., Cytokine Growth Factor Rev., 2003, 14, 155-174). IL-17A and IL-17F are expressed by Th17, a recently defined autoimmune-associated subset of T helper cells that also express the signature cytokines IL-21 and IL-22 (Korn et al., Ann. Rev. Immunol., 2009, 27, 485-517). IL-17A and IL-17F are expressed as homodimers, but can also be expressed as IL-17A / F heterodimers (Wright et al., J. Immunol., 2008, 181, 2799-2805). IL-17A and F signal via the receptors IL-17R, IL-17RC, or the IL-17RA / RC receptor complex (Gaffen, Cytokine, 2008, 43, 402-407). Both IL-17A and IL-17F are associated with several autoimmune diseases.
[0003] Therefore, the compounds according to the present invention, which are potent modulators of human IL-17 activity, are beneficial for the treatment and / or prevention of a variety of human diseases, including inflammatory disorders and autoimmune disorders.
[0004] Furthermore, the compounds according to the present invention may be useful as pharmacological criteria for use in the development of new biological tests and the search for new pharmacological agents. Therefore, the compounds of the present invention may be useful as radioligands in assays for detecting pharmacologically active compounds.
[0005] International Publication Nos. 2013 / 116682 and International Publication Nos. 2014 / 066726 relate to separate classes of chemical compounds that modulate the activity of IL-17 and are said to be useful in the treatment of medical conditions, including inflammatory diseases.
[0006] International Publication Nos. 2018 / 229079 and International Publication Nos. 2020 / 011731 describe spirocyclic molecules that act as modulators of IL-17 activity and are therefore said to be beneficial in the treatment of pathological conditions, including harmful inflammatory disorders and autoimmune disorders.
[0007] International Publication No. 2019 / 138017 describes a class of fusion bicyclic imidazole derivatives, including benzimidazole derivatives and their analogues, which are said to act as modulators of IL-17 activity and are therefore beneficial in the treatment of pathological conditions, including adverse inflammatory disorders and autoimmune disorders.
[0008] International Publication No. 2019 / 223718 describes heterocyclic compounds (including benzimidazole derivatives) that inhibit IL-17A and are useful as immunomodulators.
[0009] Heterocyclic compounds that are said to be able to modulate IL-17 activity are also described in International Publication Nos. 2020 / 127685, 2020 / 146194, and 2020 / 182666.
[0010] International Publications 2020 / 120140 and 2020 / 120141, as well as concurrently pending international applications PCT / IB2020 / 055970, PCT / EP2020 / 067758, and PCT / EP2020 / 067759 (published on December 30, 2020, as International Publications 2020 / 261141, 2020 / 260425, and 2020 / 260426, respectively), describe a distinct class of chemical compounds that act as modulators of IL-17 activity and are therefore said to be beneficial in treating pathological conditions, including adverse inflammatory disorders and autoimmune disorders.
[0011] However, none of the prior art available to date discloses or suggests the precise structural class of the substituted imidazo[1,2-b]pyridazine derivatives provided by the present invention. [Overview of the project] [Means for solving the problem]
[0012] In addition to being potent modulators of human IL-17 activity, the compounds according to the present invention possess other remarkable advantages. In particular, the compounds of the present invention exhibit valuable metabolic stability, as determined by either microsomal or hepatocyte incubation. The compounds of the present invention also exhibit useful permeability, as determined by standard assays, such as Caco-2 permeability assays.
[0013] The present invention relates to a compound of formula (I), its N-oxide, or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, E represents the base of the formula (Ea), (Eb), (Ec), (Ed), or (Ee): [ka] In the formula, the asterisk (*) represents the bonding point with the remaining part of the molecule; A represents a group of formula (Aa), (Ab), (Ac), (Ad), or (Ae):
Chemical formula
Chemical formula
[0014] The present invention also provides compounds of formula (I) as defined above, or pharmaceutically acceptable salts thereof.
[0015] The present invention also provides compounds of formula (I) defined above, or their N-oxides, or pharmaceutically acceptable salts thereof, for use in therapeutic purposes.
[0016] The present invention also provides a compound of formula (I) defined above, or its N-oxide, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of disorders characterized by the administration of an IL-17 functional modulator.
[0017] The present invention also provides the use of a compound of formula (I) defined above, or its N-oxide, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical for the treatment and / or prevention of disorders characterized by the administration of an IL-17 functional modulator.
[0018] The present invention also provides a method for treating and / or preventing a disorder characterized by the administration of an IL-17 functional modulator, comprising administering an effective amount of a compound of formula (I) as defined above, its N-oxide, or a pharmaceutically acceptable salt thereof, to a patient requiring such treatment.
[0019] Where it is stated that any of the groups in the compound of formula (I) above are optionally substituted, this group may be unsubstituted or substituted with one or more substituents. Generally, such groups are unsubstituted or substituted with one, two, three, or four substituents. Typically, such groups are unsubstituted or substituted with one, two, or three substituents. Preferably, such groups are unsubstituted or substituted with one or two substituents.
[0020] When used in medicine, the salts of the compounds of formula (I) are pharmaceutically acceptable salts. However, other salts may be useful in the preparation of the compounds of formula (I) or their pharmaceutically acceptable salts. Standard principles underlying the selection and preparation of pharmaceutically acceptable salts are described, for example, in Handbook of Pharmaceutical Salts: Properties, Selection and Use, edited by P.H. Stahl & C.G. Wermuth, Wiley-VCH, 2002. Suitable pharmaceutically acceptable salts of the compounds of formula (I) include, for example, acid addition salts that can be formed by mixing a solution of the compound of formula (I) with a solution of a pharmaceutically acceptable acid.
[0021] The present invention also includes within its scope co-crystals of the compounds of formula (I) above. The technical term "co-crystal" is used to describe a situation where neutral molecular components are present in a crystalline compound in a certain stoichiometric ratio. The preparation of pharmaceutical co-crystals enables modification of the crystalline form of the active pharmaceutical ingredient, thereby changing its physicochemical properties without impairing the intended biological activity (see Pharmaceutical Salts and Co-crystals, ed. J. Wouters & L. Quere, RSC Publishing, 2012).
[0022] Suitable alkyl groups that may be present in the compounds used in the present invention include straight-chain and branched C 1-6 alkyl groups, for example, C 1-4 alkyl groups. Typical examples include methyl and ethyl groups, as well as straight-chain or branched propyl, butyl, and pentyl groups. Specific alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2,2-dimethylpropyl and 3-methylbutyl. "C 1-6 alkoxy", "C 1-6 alkylthio", "C 1-6 alkylsulfonyl", and "C 1-6Derived expressions such as "alkylamino" should be interpreted accordingly.
[0023] As used herein, "C" 3-9 The term "cycloalkyl" refers to a monovalent group of 3 to 9 carbon atoms derived from a saturated monocyclic hydrocarbon and may include its benzo-fused analogs. Preferred C 3-9 Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, benzocyclobutenyl, cyclopentyl, indanyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclononanyl.
[0024] As used herein, "C" 4-12 The term "bicycloalkyl" refers to a monovalent group of 4 to 12 carbon atoms derived from a saturated bicyclic hydrocarbon. Typical bicycloalkyl groups include bicyclo[1.1.1]pentanyl, bicyclo[3.1.0]hexanyl, bicyclo[4.1.0]heptanyl, and bicyclo[2.2.2]octanyl.
[0025] As used herein, the term "aryl" refers to a monovalent carbocyclic aromatic group derived from a single aromatic ring or multiple fused aromatic rings. Preferred aryl groups include phenyl and naphthyl, preferably phenyl.
[0026] Preferred aryl(C 1-6 )alkyl groups include benzyl, phenylethyl, phenylpropyl, and naphthylmethyl.
[0027] As used herein, "C" 3-7The term "heterocycloalkyl" refers to a saturated monocyclic ring containing 3 to 7 carbon atoms and at least one heteroatom selected from oxygen, sulfur, and nitrogen, and may include its benzo-condensed analogs. Suitable heterocycloalkyl groups include oxetanil, azetidinil, tetrahydrofuranil, dihydrobenzo-furanil, dihydrobenzothienyl, pyrrolidinil, indolinil, isoindolinil, oxazolidinil, thiazolidinil, isothiazolidinil, imidazolidinil, tetrahydropyranil, chromanil, tetrahydrothiopyranil, piperidinil, 1,2,3,4-tetrahydroquinolinil, 1,2,3,4-tetrahydroisoquinolinil, piperazinil, 1,2,3,4-tetrahydroquinoxalinil, hexahydro-[1,2,5]thiadiazolo[2,3-a]-pyradinil, homopiperazinil, morpholinil, benzoxazinil, thiomorpholinil, azepanil, oxazepanil, diazepanil, thiadiazepanil, and azokanil.
[0028] The term "C" used herein 4-9 The term "heterobicycloalkyl" refers to a compound in which one or more carbon atoms are replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen. 4-9This corresponds to bicycloalkyl groups. Typical heterobicycloalkyl groups include 6-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]-heptanyl, 6-azabicyclo[3.2.0]heptanyl, 6-oxabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.1.1]-heptanyl, 3-azabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.2]octanyl, quinuclidinyl, and 2-oxa-5-azabicyclo[2.2.2] Examples include kutanyl, 8-oxabicyclo[3.2.1]octanyl, 3-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]-octanyl, 3,6-diazabicyclo[3.2.2]nonanyl, 3-oxa-7-azabicyclo[3.3.1]nonanyl, 3,7-dioxa-9-azabicyclo[3.3.1]nonanyl, and 3,9-diazabicyclo[4.2.1]nonanyl.
[0029] As used herein, the term “heteroaryl” refers to a monovalent aromatic group containing at least five atoms derived from a monocyclic or multi-cyclic fused ring, wherein one or more carbon atoms are replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen. Preferred heteroaryl groups include furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,4-b]-[1,4]dioxynyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl. Dinyl, pyrazolo[3,4-d]pyrimidinyl, pyrazolo[1,5-a]-pyrazinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[2,1-b]-thiazolyl, imidazo[1,2-a]pyridinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, imidazo-[4 ,5-b]pyridinyl, imidazo[1,2-b]pyridazinyl, prinyl, imidazo[1,2-a]pyrimidinyl, imidazo-[1,2-c]pyrimidinyl, imidazo[1,2-a]pyradinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]-triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyradinyl, 5,6,7,8-tetrahydro[1,2, Examples include [4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, 6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyradinyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyridadinyl, sinnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl, and clomenyl groups.
[0030] As used herein, the term "halogen" is intended to include fluorine, chlorine, bromine, and iodine atoms, typically fluorine, chlorine, or bromine.
[0031] If a compound of formula (I) has one or more chiral centers, it may exist as an enantiomer accordingly. If a compound according to the present invention has two or more chiral centers, they may further exist as diastereomers. The present invention should be understood to extend to the use of all such enantiomers and diastereomers, as well as mixtures thereof in any proportion, including racemates. Formula (I) and the formulas shown below are intended to represent all individual stereoisomers and all possible mixtures thereof unless otherwise specified or indicated. In addition, compounds of formula (I) may exist as tautomers, e.g., keto (CH2C=O)-enol (CH=CHOH) tautomers or amide (NHC=O)-hydroxyimine (N=COH) tautomers. Formula (I) and the formulas shown below are intended to represent all individual tautomers and all possible mixtures thereof unless otherwise specified or indicated.
[0032] It should be understood that each individual atom present in formula (I) or the formulas shown below may actually exist in any of its naturally occurring isotopes, with the most abundant isotope being preferred. Therefore, as an example, each individual hydrogen atom present in formula (I) or the formulas shown below may exist in any of its naturally occurring isotopes. 1 H, 2 H (deuterium), or 3 H (tritium) atoms, preferably 1 It can exist as H. Similarly, as an example, each individual carbon atom in formula (I) or the formula shown below, 12 C, 13 C, or 14 C atom, preferably a C atom. 12 It can exist as C.
[0033] In the first embodiment, E represents the base of formula (Ea). In the second embodiment, E represents the base of formula (Eb). In the third embodiment, E represents the base of formula (Ec). In the fourth embodiment, E represents the base of formula (Ed). In the fifth embodiment, E represents the base of formula (Ee).
[0034] Preferably, E represents the base of formula (Ea) or (Ed).
[0035] In general, the present invention provides compounds of formula (IA-1), (IA-2), (IA-3), (IA-4), or (IA-5), or their N-oxides, or pharmaceutically acceptable salts thereof: [ka] In the formula, A, R 1a , R 1b , and R 6 This is as defined above.
[0036] Preferably, the present invention provides compounds of formula (IA-1) or (IA-4) as defined above, or their N-oxides, or pharmaceutically acceptable salts thereof.
[0037] Generally, A represents the base of the formula (Aa), (Ab), (Ac), or (Ad).
[0038] In the first embodiment, A represents the base of formula (Aa). In the second embodiment, A represents the base of formula (Ab). In the third embodiment, A represents the base of formula (Ac). In the fourth embodiment, A represents the base of formula (Ad). In the fifth embodiment, A represents the base of formula (Ae).
[0039] Typically, A represents the base of the formula (Aa), (Ac), (Ad), or (Ae).
[0040] Preferably, A represents the base of formula (Ac).
[0041] Generally, the present invention provides compounds of formula (IB-1), (IB-2), (IB-3), (IB-4), or (IB-5), or their N-oxides, or pharmaceutically acceptable salts thereof: [ka] In the formula, E, Y, Z, R 1a , R 1b , R 2 , R 3 , R 4a , R 4b , and R 6 This is as defined above.
[0042] More specifically, the present invention provides compounds of formulas (IB-1), (IB-2), (IB-3), or (IB-4) as defined above, or their N-oxides, or pharmaceutically acceptable salts thereof.
[0043] Typically, the present invention provides compounds of formulas (IB-1), (IB-3), (IB-4), or (IB-5) as defined above, or their N-oxides, or pharmaceutically acceptable salts thereof.
[0044] Preferably, the present invention provides a compound of formula (IB-3) defined above, its N-oxide, or a pharmaceutically acceptable salt thereof.
[0045] In the first embodiment, Y represents -O-. In the second embodiment, Y represents -N(R 7 ) represents -. In the third embodiment, Y is -C(R 5a )(R 5b In the fourth embodiment, Y represents -S-. In the fifth embodiment, Y represents -S(O)-. In the sixth embodiment, Y represents -S(O)2-. In the seventh embodiment, Y represents -S(O)(NR 8 ) represents.
[0046] Typically, Y is -O-, -N(R 7 )-,-C(R 5a )(R5b )-, or -S(O)2-, where R 5a , R 5b , and R 7 This is as defined above.
[0047] Appropriately, Y is -N(R 7 )- or -C(R 5a )(R 5b )- represents, and in the formula, R 5a , R 5b , and R 7 This is as defined above.
[0048] Preferably, Y is -C(R 5a )(R 5b )- represents, and in the formula, R 5a and R 5b This is as defined above.
[0049] Generally, Z includes furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,4-b][1,4]dioxynyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, and pyrazolo[3,4-d]-pyridinyl. Midinyl, pyrazolo[1,5-a]pyradinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyridinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[1,2-b]pyridadyl Nyl, prinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-a]pyradinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyradinyl, 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo [1,5-a]pyrimidinyl, 6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]-pyraminyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, naphthilidinyl, pyridadinyl, synnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl, or clomenyl, any of these groups may optionally be substituted by one or more substituents.
[0050] Suitablely, Z represents pyrazolyl, pyrazolo[1,5-a]pyridinyl, isoxazolyl, isothiazolyl, imidazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyradinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolyl, pyridinyl, pyridadinyl, pyrimidinyl, or pyrazinyl, any of these groups may optionally be substituted by one or more substituents.
[0051] Typically, Z represents imidazolyl, triazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, or tetrazolyl, any of these groups may optionally be substituted with one or more substituents.
[0052] More specifically, Z represents [1,2,4]triazolo[4,3-a]pyridinyl or tetrazolyl, and any of these groups may optionally be substituted by one or more substituents.
[0053] Preferably, Z represents a triazolyl group, which may be optionally substituted with one or more substituents.
[0054] Typical examples of optional substituents on Z include halogens, cyanos, nitros, and C. 1-6 Alkyl, difluoromethyl, difluoroethyl, trifluoro(C) 1-6 )Alkyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, fluorobicyclo[1.1.1]-pentanyl, cyanobicyclo[1.1.1]pentanyl, spiro[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxy, hydroxy(C 1-6 ) alkyl, oxo, C 1-6Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylenedioxy, difluoromethylenedioxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkyl-amino, amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) Alkylaminosulfonyl and di(C 1-6 ) One, two, or (if possible) three substituents independently selected from the alkyl-sulfoxiimino.
[0055] Suitable examples of optional substituents on Z include halogens, cyanosides, and C12. 1-6 Alkyl, difluoromethyl, difluoroethyl, trifluoro(C) 1-6 ) Alkyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, cyanobicyclo[1.1.1]-pentanyl, and C 1-6 Examples include one, two, or (if possible) three substituents independently selected from the alkylamino.
[0056] Exemplary examples of optional substituents on Z include halogens and trifluoro(C) 1-6) One, two, or (if possible) three substituents independently selected from the alkyl group.
[0057] A preferred example of an optional substituent on Z is trifluoro(C 1-6 ) One, two, or (if possible) three substituents independently selected from the alkyl group.
[0058] Typical examples of specific substituents on Z include fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, n-propyl, isopropyl, tert-butyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluoro-cyclopropylmethyl, fluorobicyclo[1.1.1]pentanyl, cyanobicyclo[1.1.1]pentanyl, spiro-[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, oxo, methoxy, isopropio Examples include one, two, or (if possible) three substituents independently selected from xy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylenedioxy, difluoromethylenedioxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methyl-sulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, amino-carbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylamino-sulfonyl, dimethylaminosulfonyl, and dimethylsulfoxiimino.
[0059] Suitable examples of specific substituents on Z include one, two, or (where possible) three substituents independently selected from fluoro, cyano, methyl, difluoromethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, cyanobicyclo[1.1.1]pentanyl, and methylamino.
[0060] Exemplary examples of specific substituents on Z include one, two, or (if possible) three substituents independently selected from fluoro and trifluoroethyl.
[0061] Preferred examples of specific substituents on Z include one, two, or (if possible) three substituents independently selected from trifluoroethyl.
[0062] Typical values of Z include trifluoroethylpyrazolyl, (methyl)(trifluoroethyl)-pyrazolyl, pyrazolo[1,5-a]pyridinyl, methylindazolyl, trifluoroethylisoxazolyl, (methyl)-(trifluoroethyl)isoxazolyl, trifluoroethylisothiazolyl, trifluoroethylimidazolyl, cyclopropylmethylimidazolyl, (methyl)(trifluoroethyl)imidazolyl, imidazo[1,2-a]-pyridinyl, difluoroethyltriazolyl, trifluoroethyltriazolyl, difluorocyclopropyltriazolyl, difluorocyclobutyltriazolyl, cyclopropylmethyltriazolyl, cyanobicyclo[1.1.1]pentanyl- Examples include triazolyl, (fluoro)(trifluoroethyl)triazolyl, (methyl)(trifluoroethyl)triazolyl, (difluoromethyl)(trifluoroethyl)triazolyl, (cyclopropylmethyl)(difluoromethyl)triazolyl, (methyl-amino)(trifluoroethyl)triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, fluoro[1,2,4]triazolo[4,3-a]pyridinyl, cyano[1,2,4]triazolo[4,3-a]pyridinyl, benzotriazolyl, trifluoroethyltetrazolyl, trifluoroethylpyridinyl, trifluoroethylpyridazinyl, trifluoroethylpyrimidinyl, and trifluoroethylpyradinyl.
[0063] Examples of Z values include cyclopropylmethylimidazolyl, difluoroethyl-triazolyl, trifluoroethyltriazolyl, difluorocyclobutyltriazolyl, cyclopropylmethyltriazolyl, cyanobicyclo[1.1.1]pentanyltriazolyl, fluoro[1,2,4]triazolo[4,3-a]pyridinyl, cyano[1,2,4]-triazolo[4,3-a]pyridinyl, and trifluoroethyltetrazolyl.
[0064] Appropriate values for Z include fluoro[1,2,4]triazolo[4,3-a]pyridinyl and trifluoroethyltetrazolyl.
[0065] A suitable value for Z is trifluoroethyltriazolyl.
[0066] Preferably, Z represents a base of the formula (Za), (Zb), (Zc), (Zd), (Ze), (Zf), (Zg), (Zh), (Zj), (Zk), (Zl), (Zm), (Zn), (Zp), (Zq), (Zr), (Zs), (Zt), (Zu), (Zv), (Zw), (Zx), (Zy), (Zz), (Zaa), or (Zab): [ka] [ka] During the ceremony, An asterisk (*) represents a bond point with the rest of the molecule; R 1z is hydrogen, C 1-6 Alkyl, difluoromethyl, difluoroethyl, trifluoro(C) 1-6 )-Alkyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluoro-cyclopropylmethyl, fluorobicyclo[1.1.1]pentanyl, cyanobicyclo[1.1.1]pentanyl, spiro[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxy(C 2-6 ) Alkyl, C 1-6 Alkyl sulfonyl, amino(C 2-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonyl, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, or di(C 1-6 ) represents alkylaminosulfonyl; and R2z These are hydrogen, halogen, cyano, nitro, and C 1-6 Alkyl, difluoromethyl, trifluoro(C) 1-6 )Alkyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropyl-methyl, difluorocyclopropylmethyl, fluorobicyclo[1.1.1]pentanyl, cyanobicyclo[1.1.1]-pentanyl, spiro[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxy, hydroxy(C 1-6 ) Alkyl, C 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkyl-amino, amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) Alkylaminosulfonyl, or di(C 1-6 ) Represents alkyl-sulfoxiimino.
[0067] The specific values of Z include the bases of the formulas (Zk), (Zm), (Zp), (Zq), (Zt), (Zu), (Zv), (Zw), and (Zx) defined above.
[0068] A suitable value for Z includes the bases of equations (Zu) and (Zw) defined above.
[0069] More precisely, Z represents the base of equation (Zq) defined above.
[0070] Typically, R 1z is hydrogen, C 1-6 Alkyl, difluoroethyl, trifluoro(C) 1-6 ) represents alkyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, or cyanobicyclo[1.1.1]pentanyl.
[0071] R 1z Appropriate values for include hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, fluorobicyclo[1.1.1]pentanyl, cyano-bicyclo[1.1.1]pentanyl, spiro[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxyethyl, hydroxyisopropyl, methylsulfonyl, aminoethyl, dimethylaminomethyl, acetyl, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, and dimethylaminosulfonyl.
[0072] R 1z Typical values include hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl, difluoroethyl, trifluoroethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, and cyanobicyclo[1.1.1]pentanyl.
[0073] R 1zExemplary values include difluoroethyl, trifluoroethyl, difluorocyclobutyl, cyclopropylmethyl, and cyanobicyclo[1.1.1]pentanyl.
[0074] Preferably, R 1z This represents trifluoroethyl.
[0075] Typically, R 2z These are hydrogen, halogen, cyano, and C 1-6 Alkyl, trifluoro(C) 1-6 ) Alkyl, cyclopropylmethyl, difluorocyclopropylmethyl, or C 1-6 Represents alkylamino.
[0076] Preferably, R 2z R represents hydrogen, halogen, or cyano. In the first embodiment, R 2z represents hydrogen. In the second embodiment, R 2z represents halogens, particularly fluorocarbons. In the third embodiment, R 2z This represents cyano.
[0077] R 2zAppropriate values for hydrogen include fluoromethyl, chloromethyl, bromomethyl, cyanomethyl, nitromethyl, ethyl, n-propyl, isopropyl, tert-butylmethyl, difluoromethyl, trifluoromethyl, trifluoro-ethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, cyclopropyl, difluorocyclopropyl, difluorocyclobutyl, cyclopropylmethyl, difluorocyclopropylmethyl, fluorobicyclo[1.1.1]-pentanyl, cyanobicyclo[1.1.1]pentanyl, spiro[2.2]pentanyl, methylspiro[2.2]pentanyl, hydroxymethyl, hydroxyethyl, hydroxyisopropyl Examples include propyl, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, ethylamino, dimethylamino, amino-methyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methylsulfonyl-amino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and dimethylsulfoxyimino.
[0078] R 2z Typical values include hydrogen, fluoro, cyano, methyl, difluoromethyl, trifluoroethyl, trifluoropropyl, 2-methyl-3,3,3-trifluoropropyl, cyclopropylmethyl, difluorocyclopropylmethyl, and methylamino.
[0079] R 2z Suitable values include hydrogen, fluoro, and cyano.
[0080] R 2z The specific value is fluoro.
[0081] In the first embodiment, R 1a represents hydrogen. In the second embodiment, R1a represents fluoro. In the third embodiment, R 1a represents chloro. In the fourth embodiment, R 1a represents methyl. In the fifth embodiment, R 1a represents difluoromethyl. In the sixth embodiment, R 1a This represents trifluoromethyl.
[0082] Typically, R 1a represents hydrogen, fluoro, chloro, or methyl.
[0083] In general, R 1a This represents hydrogen or fluorocarbon.
[0084] Preferably, R 1a This represents hydrogen.
[0085] In the first embodiment, R 1b represents hydrogen. In the second embodiment, R 1b represents fluoro. In the third embodiment, R 1b represents chloro. In the fourth embodiment, R 1b represents methyl. In the fifth embodiment, R 1b represents difluoromethyl. In the sixth embodiment, R 1b This represents trifluoromethyl.
[0086] Typically, R 1b represents hydrogen, fluoro, chloro, or methyl.
[0087] In general, R 1b This represents hydrogen or fluorocarbon.
[0088] Preferably, R 1b This represents hydrogen.
[0089] Preferably, R 2 C 3-9 Cycloalkyl, C 4-12 Bicycloalkyl, or C 3-7This represents a heterocycloalkyl group, and any of these groups may optionally be substituted with one or more substituents.
[0090] Appropriately, R 2 C 3-9 Cycloalkyl or C 4-12 Represents a bicycloalkyl group, where any of these groups may optionally be substituted by one or more substituents.
[0091] R 2 Typical examples include cyclobutyl, bicyclo[1.1.1]pentanyl, azetidinyl, pyrrolidinyl, tetrahydropyranyl, and morpholinyl, any of which may be optionally substituted with one or more substituents.
[0092] R 2 Suitable examples include bicyclo[1.1.1]pentanyl and pyrrolidinyl, in which either of these groups may be optionally substituted with one or more substituents.
[0093] R 2 A preferred example of this is bicyclo[1.1.1]pentanyl, which may optionally be substituted with one or more substituents.
[0094] R 2 Typical examples of the optional substituents mentioned above include one, two, three, or four substituents that can be selected independently of the halogen.
[0095] R 2 Typical examples of the specific substituents mentioned above include one, two, three, or four substituents that can be selected independently of fluoropolymers.
[0096] R 2Typical values include difluorocyclobutyl, fluorobicyclo[1.1.1]pentanyl, difluoroazetidinyl, difluoropyrrolidinyl, tetrafluoropyrrolidinyl, difluorotetrahydropyranyl, and tetrafluoromorpholinyl.
[0097] R 2 Appropriate values for this include fluorobicyclo[1.1.1]pentanyl and tetrafluoropyrrolidinyl.
[0098] R 2 A preferred value for this is fluorobicyclo[1.1.1]pentanyl.
[0099] In the first embodiment, R 2a is C 1-6 Represents alkyl. In the second embodiment, R 2a C is substituted in some cases. 3-9 This represents a cycloalkyl group.
[0100] Typically, R 2a is C 1-6 Represents alkyl, or R 2a represents cyclobutyl, which may optionally be substituted by one or more substituents.
[0101] R 2a Typical examples of the optional substituents above include halogens, cyanos, nitros, and C. 1-6 Alkyl, trifluoromethyl, hydroxy, hydroxy(C) 1-6 ) alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, amino(C 1-6 ) Alkyl, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, C 2-6 Alkylcarbonylamino, C 2-6Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl and di(C 1-6 Examples include one, two, or three substituents independently selected from alkylaminosulfonyl compounds.
[0102] R 2a Suitable examples of the optional substituents mentioned above include one, two, or three substituents that can be selected independently of the halogen.
[0103] R 2a Typical examples of the above specific substituents include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, trifluoromethylhydroxy, hydroxymethyl, oxo, methoxy, tert-butoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, aminomethyl, aminoethyl, methylamino, tert-butylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, and dimethylaminosulfonyl.
[0104] R 2a Preferred examples of the specific substituents mentioned above include one, two, or three substituents selected independently of fluoro.
[0105] R 2aExemplary examples of specific values include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclobutyl, and difluorocyclobutyl.
[0106] In the first embodiment, R 3 -NR 3a R 3b This represents R. In the second embodiment, R 3 This represents the base of the formula (Wa) defined above.
[0107] In the first embodiment, R 3a represents hydrogen. In the second embodiment, R 3a C 1-6 Represents alkyl, particularly methyl or ethyl. In the first embodiment of the present invention, R 3a represents methyl. In a second embodiment of the embodiment, R 3a represents ethyl.
[0108] Typically, R 3b C 1-6 Alkyl or C 3-7 Cycloalkyl (C 1-6 ) represents an alkyl group, and any of these groups may optionally be substituted by one or more substituents.
[0109] Preferably, R 3b C 1-6 This represents an alkyl group, which may optionally be substituted by one or more substituents.
[0110] In the first embodiment, R 3b C is substituted in some cases. 1-6 Represents alkyl. In the second embodiment, R 3b C is substituted in some cases. 3-7 Represents a cycloalkyl group. In the third embodiment, R 3b C is substituted in some cases. 3-7 Cycloalkyl (C 1-6 ) represents alkyl. In the fourth embodiment, R 3b C is substituted in some cases.4-12 Represents bicycloalkyl. In the fifth embodiment, R 3b represents an aryl that may be substituted. In the sixth embodiment, R 3b This is the aryl(C) which may be substituted in some cases. 1-6 ) represents alkyl. In the seventh embodiment, R 3b C is substituted in some cases. 3-7 Represents heterocycloalkyl. In the eighth embodiment, R 3b C is substituted in some cases. 3-7 Heterocycloalkyl (C 1-6 ) represents alkyl. In the ninth embodiment, R 3b R represents a heteroaryl that may be substituted. In the tenth embodiment, R 3b This is a heteroaryl (C) that may be substituted in some cases. 1-6 ) Represents alkyl.
[0111] R 3b Suitable examples include ethyl, propyl, isopropyl, 2-methylpropyl, and cyclopropylmethyl, any of which may optionally be substituted with one or more substituents.
[0112] R 3b Typical examples include ethyl, isopropyl, 2-methylpropyl, and cyclopropylmethyl, any of which may be optionally substituted with one or more substituents.
[0113] R 3b A preferred example is ethyl, which may optionally be substituted with one or more substituents.
[0114] R 3b Typical examples of the optional substituents above include halogens, cyanos, nitros, and C. 1-6 Alkyl, trifluoromethyl, hydroxy, C 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, C 1-6Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkyl-amino, di(C 1-6 ) Alkylamino, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, amino-carbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) alkylaminosulfonyl and di(C 1-6 Examples include one, two, or three substituents independently selected from the alkylsulfoxiimino.
[0115] R 3b Suitable examples of the optional substituents above include halogens, trifluoromethyl compounds, and C 1-6 Examples include one, two, or three substituents independently selected from alkylamino-carbonyl groups.
[0116] R 3b Suitable examples of the optional substituents mentioned above include one, two, or three substituents that can be selected independently of the halogen.
[0117] R 3bTypical examples of the specific substituents listed above include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, methylthio, methylsulfinyl, methylsulfonyl, ethylsulfonyl, amino, methylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and dimethylsulfoxiimino.
[0118] R 3b Suitable examples of the specific substituents mentioned above include one, two, or three substituents independently selected from fluoro, trifluoromethyl, and methylamino-carbonyl.
[0119] R 3b Preferred examples of the specific substituents mentioned above include one, two, or three substituents selected independently of fluoro.
[0120] R 3b Typical values include difluoroethyl, trifluoroethyl, trifluoroisopropyl, methylaminocarbonyl-2-methylpropyl, (cyclopropyl)(trifluoromethyl)methyl, and difluorocyclopropylmethyl. Further values include difluoropropyl.
[0121] R 3b Typical values include trifluoroethyl, difluoropropyl, trifluoroisopropyl, methylaminocarbonyl-2-methylpropyl, and (cyclopropyl)(trifluoromethyl)-methyl.
[0122] R 3bAppropriate values for this include trifluoroethyl, trifluoroisopropyl, methylaminocarbonyl-2-methylpropyl, and (cyclopropyl)(trifluoromethyl)methyl.
[0123] R 3b A suitable value for this is trifluoroethyl.
[0124] In the first embodiment, W represents a optionally substituted saturated monocyclic ring residue containing 3 to 6 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms. In the first aspect of that embodiment, W represents a optionally substituted saturated monocyclic ring residue containing 3 or 4 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms.
[0125] In the second embodiment, W represents a residue of an optionally substituted saturated bicyclic ring system containing 4 to 10 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms. In the first aspect of that embodiment, W represents a residue of an optionally substituted saturated bicyclic ring system containing 5, 6, or 7 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms.
[0126] In the third embodiment, W represents a residue of an optionally substituted saturated spirocyclic ring system containing 5 to 10 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms. In the first aspect of that embodiment, W represents a residue of an optionally substituted saturated spirocyclic ring system containing 5, 6, or 7 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 further heteroatoms independently selected from N, O, and S, but containing 1 or fewer O or S atoms.
[0127] Preferably, W represents an optionally substituted saturated monocyclic ring residue containing 3 or 4 carbon atoms, 1 nitrogen atom, and 0 or 1 oxygen atom. In the first embodiment, W represents an optionally substituted saturated monocyclic ring residue containing 3 or 4 carbon atoms and 1 nitrogen atom. In the first aspect of that embodiment, W represents an optionally substituted saturated monocyclic ring residue containing 3 carbon atoms and 1 nitrogen atom. In the second aspect of that embodiment, W represents an optionally substituted saturated monocyclic ring residue containing 4 carbon atoms and 1 nitrogen atom. In the second embodiment, W represents an optionally substituted saturated monocyclic ring residue containing 4 carbon atoms, 1 nitrogen atom, and 1 oxygen atom.
[0128] In the first embodiment, the group of formula (Wa) represents a saturated monocyclic ring containing one nitrogen atom and no further heteroatoms (i.e., an optionally substituted azetidine-1-yl, pyrrolidine-1-yl, piperidine-1-yl, or hexahydroazepine-1-yl ring). In the second embodiment, the group of formula (Wa) represents a saturated monocyclic ring containing one nitrogen atom and one further heteroatom selected from N, O, and S. In the first aspect of that embodiment, the group of formula (Wa) is an optionally substituted morpholine-4-yl moiety. In the third embodiment, the group of formula (Wa) represents a saturated monocyclic ring containing one nitrogen atom and two further heteroatoms selected from N, O, and S, one or less of which are O or S. In the fourth embodiment, the group of formula (Wa) represents a saturated monocyclic ring containing one nitrogen atom and three further heteroatoms selected from N, O, and S, of which one or less are O or S.
[0129] Typical values for the group in formula (Wa) include azetidine-1-yl, pyrrolidine-1-yl, oxazolidine-3-yl, thiazolidin-3-yl, isothiazolidine-2-yl, imidazolidine-1-yl, piperidine-1-yl, piperazine-1-yl, homopiperazine-1-yl, morpholine-4-yl, thiomorpholine-4-yl, azepan-1-yl, [1,4]oxazepan-4-yl, [1,4]diazepan-1-yl, [1,4]thiadiazepan-4-yl, azocan-1-yl, 3-azabicyclo-[3.1.0]hexane- 3-yl, 2-oxa-5-azabicyclo[2.2.1]heptane-5-yl, 6-azabicyclo[3.2.0]heptane-6-yl, 3-azabicyclo[3.1.1]heptane-3-yl, 6-oxa-3-azabicyclo[3.1.1]heptane-3-yl, 3-azabicyclo-[4.1.0]heptane-3-yl, 2-oxa-5-azabicyclo[2.2.2]octane-5-yl, 3-azabicyclo[3.2.1]octane-3-yl, 8-azabicyclo[3.2.1]octane-8-yl, 3-oxa-8-azabicyclo[3.2.1 ]octane-8-yl, 3,8-diazabicyclo-[3.2.1]octane-3-yl, 3,8-diazabicyclo[3.2.1]octane-8-yl, 3,6-diazabicyclo[3.2.2]nonane-3-yl, 3,6-diazabicyclo[3.2.2]nonane-6-yl, 3-oxa-7-azabicyclo[3.3.1]nonane-7-yl, 3,7-dioxa-9-azabicyclo[3.3.1]nonane-9-yl, 3,9-diazabicyclo[4.2.1]nonane-3-yl, 3,9-diazabicyclo[4.2.1]-nonane-9-yl, 5-azabi Spiro[2.3]hexane-5-yl, 5-azaspiro[2.4]heptane-5-yl, 2-azaspiro[3.3]heptane-2-yl, 2-oxa-6-azaspiro[3.3]heptane-6-yl, 3-oxa-6-azaspiro[3.3]heptane-6-yl, 6-thia-2-azaspiro[3.3]heptane-2-yl, 2-oxa-6-azaspiro[3.4]octane-6-yl, 2-oxa-6-azaspiro[3.5]nonane-6-yl, 7-oxa-2-azaspiro[3.5]nonane-2-yl, 2-oxa-7-azaspiro[3.Examples include [5]nonane-7-yl, 2,4,8-triazaspiro[4.5]-decane-2-yl, 2,4,8-triazaspiro[4.5]decane-4-yl, and 2,4,8-triazaspiro[4.5]decane-8-yl, any of these groups may optionally be substituted with one or more substituents.
[0130] In the first embodiment, the group of formula (Wa) is unsubstituted. In the second embodiment, the group of formula (Wa) is substituted with one or more substituents, typically 1 to 6 substituents, preferably 2 to 4 substituents. In the first aspect of the embodiment, the group of formula (Wa) is substituted with 1 substituent. In the second aspect of the embodiment, the group of formula (Wa) is substituted with 2 substituents. In the third aspect of the embodiment, the group of formula (Wa) is substituted with 3 substituents. In the fourth aspect of the embodiment, the group of formula (Wa) is substituted with 4 substituents. In the fifth aspect of the embodiment, the group of formula (Wa) is substituted with 5 substituents. In the sixth aspect of the embodiment, the group of formula (Wa) is substituted with 6 substituents.
[0131] Typical examples of optional substituents on the base of formula (Wa) include halogens, C 1-6 Alkyl, trifluoromethyl, hydroxy, hydroxy(C) 1-6 ) Alkyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkoxy(C) 1-6 ) Alkyl, C 1-6 Alkylthio, C 1-6 Alkylsulfonyl, cyano, oxo, formyl, C 2-6 Alkylcarbonyl, carboxy, carboxy(C 1-6 ) Alkyl, C 2-6 Alkoxycarbonyl, C 2-6 Alkoxycarbonyl (C 1-6 )alkyl, amino, amino(C 1-6 ) Alkyl, C 1-6 Alkylamino, di(C 1-6 ) Alkyl-amino, C2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkylsulfonylamino, aminocarbonyl, C 1-6 Alkylaminocarbonyl and di(C 1-6 Examples include alkylaminocarbonyl compounds.
[0132] A suitable example of an optional substituent on the group of formula (Wa) is a halogen.
[0133] Typical examples of specific substituents on the group of formula (Wa) include fluoro, chloro, bromo, methyl, ethyl, isopropyl, trifluoromethyl, hydroxy, hydroxymethyl, hydroxyethyl, methoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, methoxymethyl, methylthio, ethylthio, methylsulfonyl, cyano, oxo, formyl, acetyl, ethylcarbonyl, tert-butylcarbonyl, carboxy, carboxymethyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, amino, aminomethyl, methylamino, ethylamino, dimethylamino, acetylamino, tert-butoxycarbonylamino, methylsulfonylamino, aminocarbonyl, methylaminocarbonyl, and dimethylaminocarbonyl.
[0134] A preferred example of a specific substituent on the group of formula (Wa) is fluoro.
[0135] In general, R 4a represents hydrogen or fluoro, or R 4a is C 1-6 This represents an alkyl group, which may optionally be substituted by one or more substituents.
[0136] Typically, R 4a represents hydrogen, or R 4a is C 1-6This represents an alkyl group, which may optionally be substituted by one or more substituents.
[0137] Preferably, R 4a C 1-6 This represents an alkyl group, which may optionally be substituted by one or more substituents.
[0138] In the first embodiment, R 4a represents hydrogen. In the second embodiment, R 4a represents fluoro. In the third embodiment, R 4a represents hydroxyl. In the fourth embodiment, R 4a C 1-6 R represents an alkyl group, particularly a methyl or ethyl group, which may optionally be substituted with one or more substituents. In the first embodiment of the embodiment, 4a R represents a substituted methyl group, if applicable. In a second aspect of the embodiment, R 4a This represents ethyl substituted in some cases.
[0139] R 4a Typical examples of the optional substituents above include halogens, cyano, nitro, hydroxy, and C. 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, C 2-6 Alkyl-carbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkyl-carbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di-(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6Alkylaminosulfonyl, di(C 1-6 )alkylamino-sulfonyl and di(C 1-6 Examples include one, two, or three substituents independently selected from the alkylsulfoxiimino.
[0140] R 4a Suitable examples of the optional substituents mentioned above include one, two, or three substituents that can be selected independently of the halogen.
[0141] R 4a Typical examples of the above specific substituents include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, hydroxy, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, methylthio, methylsulfinyl, methylsulfonyl, ethylsulfonyl, amino, methylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylamino-carbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylamino-sulfonyl, and dimethylsulfoxyimino.
[0142] R 4a Preferred examples of the specific substituents mentioned above include one, two, or three substituents selected independently of fluoro.
[0143] R 4a Examples of values include hydrogen, fluoro, hydroxy, methyl, difluoroethyl, and trifluoroethyl.
[0144] R 4a Typical values include methyl, difluoroethyl, and trifluoroethyl.
[0145] R 4a A suitable value for this is difluoroethyl.
[0146] In general, R 4b is hydrogen, fluorocarbon, or C 1-6 Represents alkyl.
[0147] In the first embodiment, R 4b represents hydrogen. In the second embodiment, R 4b represents fluoro. In the third embodiment, R 4b C 1-6 The group represents an alkyl group, particularly a methyl or ethyl group, which may be unsubstituted or substituted with one or more substituents. In the first embodiment of the embodiment, R 4b R represents an unsubstituted methyl or substituted methyl. In a second aspect of the embodiment, R 4b This represents unsubstituted ethyl or substituted ethyl.
[0148] R 4b Typical examples of the optional substituents above include halogens, cyano, nitro, hydroxy, and C. 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, C 2-6 Alkyl-carbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkyl-carbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di-(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 )alkylamino-sulfonyl and di(C 1-6Examples include one, two, or three substituents independently selected from the alkylsulfoxiimino.
[0149] R 4b Typical examples of the above specific substituents include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, hydroxy, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, methylthio, methylsulfinyl, methylsulfonyl, ethylsulfonyl, amino, methylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylamino-carbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylamino-sulfonyl, and dimethylsulfoxyimino.
[0150] R 4b Typical values include hydrogen and fluorocarbons.
[0151] Alternatively, R 4a and R 4b These may combine to form a substituted annular portion, depending on the case. Therefore, R 4a and R 4b They both, together with the carbon atoms to which they are bonded, C 3-7 Cycloalkyl or C 3-7 The group may represent a heterocycloalkyl group, and any of these groups may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0152] In the first embodiment, R 4a and R 4b They both, together with the carbon atoms to which they are bonded, C 3-7A cycloalkyl group can be preferably represented, and this group may be unsubstituted or substituted with one or more substituents, typically one or two substituents. A general example of such embodiments is R 4a and R 4b Together with the carbon atoms to which they are both bonded, these groups can suitably represent cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, any of which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. A specific example of this embodiment is R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent cyclobutyl or cyclohexyl, and either of these groups may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In the first embodiment of the embodiment, R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent a cyclopropyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a second aspect of the embodiment, R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent a cyclobutyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a third aspect of the embodiment, R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent a cyclopentyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a fourth aspect of the embodiment, R 4a and R 4bThese, together with the carbon atoms to which they are both bonded, can suitably represent a cyclohexyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0153] In the second embodiment, R 4a and R 4b They both, together with the carbon atoms to which they are bonded, C 3-7 A heterocycloalkyl group can be suitably represented, and this group may be unsubstituted or substituted with one or more substituents, typically one or two substituents. A general example of such embodiments is R 4a and R 4b Together with the carbon atoms to which they are both bonded, these can suitably represent oxetanyl, pyrrolidinyl, tetrahydropyranyl, or piperidinyl, any of which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. A specific example of this embodiment is R 4a and R 4b Together with the carbon atom to which they are both bonded, they can suitably represent pyrrolidinyl, tetrahydropyranyl, or piperidinyl, any of which of these groups may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In the first embodiment of the embodiment, R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent an oxetanyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a second aspect of the embodiment, R 4a and R 4bTogether with the carbon atoms to which they are both bonded, they can suitably represent a pyrrolidinyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a third aspect of the embodiment, R 4a and R 4b Together with the carbon atoms to which they are both bonded, they can suitably represent a tetrahydropyranyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents. In a fourth aspect of the embodiment, R 4a and R 4b These, together with the carbon atoms to which they are both bonded, can suitably represent a piperidinyl ring, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0154] Typically, R 4a and R 4b Together with the carbon atoms to which they are both bonded, these may represent cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, pyrrolidinyl, tetrahydropyranyl, or piperidinyl, any of these groups may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0155] Appropriately, R 4a and R 4b Together with the carbon atoms to which they are both bonded, these groups may represent cyclohexyl or tetrahydropyranyl, and either of these groups may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0156] Preferably, R 4a and R 4bThese groups, together with the carbon atoms to which they are bonded, may represent a cyclohexyl group, which may be unsubstituted or substituted with one or more substituents, typically one or two substituents.
[0157] R 4a and R 4b A typical example of an optional substituent on the cyclic portion formed by is C 1-6 Alkyl, halogen, cyano, trifluoromethyl, trifluoroethyl, hydroxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkyl-sulfinyl, C 1-6 Alkyl sulfonyl, C 2-6 Alkylcarbonyl, C 2-6 Alkoxycarbonyl, amino, C 1-6 Alkyl-amino and di(C) 1-6 Examples include one, two, or three substituents independently selected from the alkylamino.
[0158] R 4a and R 4b Preferred examples of optional substituents on the cyclic portion formed by include one, two, or three substituents independently selected from the halogen.
[0159] R 4a and R 4b Typical examples of specific substituents on the cyclic moiety formed by include one, two, or three substituents independently selected from methyl, fluoro, chloro, bromo, cyano, trifluoromethyl, trifluoroethyl, hydroxy, methoxy, methylthio, methylsulfinyl, methylsulfonyl, acetyl, methoxycarbonyl, ethoxycarbonyl, amino, methyl-amino, and dimethylamino.
[0160] R 4a and R 4bPreferred examples of specific substituents on the cyclic portion formed by include one, two, or three substituents independently selected from fluoro.
[0161] R 4a and R 4b Typical examples of cyclic moieties formed by these compounds include cyclopropyl, difluorocyclobutyl, cyclopentyl, difluorocyclohexyl, oxetanyl, methoxycarbonyl-pyrrolidinyl, tetrahydropyranyl, piperidinyl, and methoxycarbonylpiperidinyl.
[0162] R 4a and R 4b Typical examples of the cyclic portions formed by this process include difluorocyclohexyl and tetrahydropyranil.
[0163] R 4a and R 4b A preferred example of the cyclic portion formed by this is difluorocyclohexyl.
[0164] In the first embodiment, R 5a represents hydrogen. In the second embodiment, R 5a represents fluoro. In the third embodiment, R 5a represents methyl. In the fourth embodiment, R 5a represents difluoromethyl. In the fifth embodiment, R 5a This represents trifluoromethyl.
[0165] Typically, R 5a represents hydrogen, fluoro, or trifluoromethyl.
[0166] Preferably, R 5a This represents fluoromethyl or trifluoromethyl.
[0167] Appropriately, R 5a represents fluoro.
[0168] In the first embodiment, R5b represents hydrogen. In the second embodiment, R 5b represents fluoro. In the third embodiment, R 5b represents methyl. In the fourth embodiment, R 5b represents hydroxyl.
[0169] Typically, R 5b represents hydrogen, fluoro, or hydroxyl.
[0170] Preferably, R 5b This represents fluoro or hydroxy.
[0171] Appropriately, R 5b represents fluoro.
[0172] Alternatively, R 5a and R 5b They may come together to form a spiro bond. Therefore, R 5a and R 5b These may together represent a cyclopropyl group with the carbon atoms to which they are both bonded.
[0173] Typically, R 6 は-OR 6a Or -NR 6b R 6c Represents, or R 6 C 1-6 Alkyl, C 3-9 Cycloalkyl, C 3-9 Cycloalkyl (C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, heteroaryl, or heteroaryl-(C 1-6 ) represents alkyl, and any of these groups may optionally be substituted by one or more substituents.
[0174] Appropriately, R 6 は-OR 6a Or -NR 6b R 6c Represents, or R 6represents an aryl or heteroaryl group, and any of these groups may optionally be substituted by one or more substituents.
[0175] Preferably, R 6 は-OR 6a Represents, or R 6 represents a heteroaryl group, which may optionally be substituted by one or more substituents.
[0176] In the first embodiment, R 6 C is substituted in some cases. 1-6 Represents alkyl. In the second embodiment, R 6 C is substituted in some cases. 3-9 Represents a cycloalkyl group. In the third embodiment, R 6 C is substituted in some cases. 3-9 Cycloalkyl (C 1-6 ) represents alkyl. In the fourth embodiment, R 6 represents an aryl that may be substituted. In the fifth embodiment, R 6 This is the aryl(C) which may be substituted in some cases. 1-6 ) represents alkyl. In the sixth embodiment, R 6 C is substituted in some cases. 3-7 Represents heterocycloalkyl. In the seventh embodiment, R 6 C is substituted in some cases. 3-7 Heterocycloalkyl (C 1-6 ) represents alkyl. In the eighth embodiment, R 6 R represents a heteroaryl that may be substituted. In the ninth embodiment, R 6 This is a heteroaryl (C) that may be substituted in some cases. 1-6 ) represents alkyl. In the tenth embodiment, R 6 は-OR 6a This represents. In the 11th embodiment, R 6 -NR 6a R 6b It represents.
[0177] R 6 A typical example of this is -OR 6aor -NR 6a R 6b Examples include methyl, ethyl, propyl, 2-methylpropyl, butyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclohexylmethyl, phenyl, benzyl, phenylethyl, pyrazolyl, isoxazolyl, oxadiazolyl, triazolyl, pyridinyl, triazolyl-methyl, benzotriazolylmethyl, or pyridinylmethyl, any of these groups may optionally be substituted with one or more substituents.
[0178] R 6 Typical examples include -OR 6a or -NR 6a R 6b ; and phenyl, pyrazolyl, isoxazolyl, oxadiazolyl, or triazolyl, any of these groups may optionally be substituted with one or more substituents.
[0179] R 6 An exemplary example of this is -OR 6a Examples include pyrazolyl, isoxazolyl, oxadiazolyl, or triazolyl, any of these groups may optionally be substituted with one or more substituents.
[0180] R 6 Suitable examples include pyrazolyl, isoxazolyl, oxadiazolyl, and triazolyl, any of which may be optionally substituted with one or more substituents.
[0181] R 6 Suitable examples include pyrazolyl and oxadiazolyl, in which either of these groups may be optionally substituted with one or more substituents.
[0182] R 6 A specific example of this is oxadiazolyl, which may optionally be substituted by one or more substituents.
[0183] R 6 Typical examples of the optional substituents above include halogens, cyanos, nitros, and C. 1-6 Alkyl, trifluoromethyl, cyclopropyl, phenyl, fluorophenyl, hydroxy, hydroxy(C) 1-6 ) alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, amino(C 1-6 ) Alkyl, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, pyrrolidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkylcarbonylamino-(C 1-6 ) Alkyl, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkyl-carbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 )alkylamino-sulfonyl and di(C 1-6 Examples include one, two, or three substituents independently selected from the alkylsulfoxyiminyl.
[0184] R 6 Suitable examples of the optional substituents above include halogens and C 1-6 Examples include one, two, or three substituents independently selected from alkyl and cyclopropyl groups.
[0185] R 6 A preferred example of the above optional substituent is C 1-6Examples include one, two, or three substituents independently selected from alkyl and cyclopropyl groups.
[0186] R 6 Typical examples of the specific substituents listed above include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, cyclopropyl, phenyl, fluorophenyl, hydroxy, hydroxymethyl, oxo, methoxy, tert-butoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, aminomethyl, aminoethyl, methyl-amino, tert-butylamino, dimethylamino, pyrrolidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, acetylamino, acetylaminoethyl, methoxycarbonylamino, methylsulfonyl-amino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and dimethylsulfoxyiminyl.
[0187] R 6 Suitable examples of the specific substituents mentioned above include one, two, or three substituents independently selected from fluoro, methyl, ethyl, isopropyl, and cyclopropyl.
[0188] R 6 Preferred examples of the specific substituents mentioned above include one, two, or three substituents independently selected from methyl, ethyl, isopropyl, and cyclopropyl.
[0189] R 6Examples of the above specific values include methyl, difluoromethyl, methylsulfonylmethyl, aminomethyl, methylaminomethyl, difluoroethyl, carboxyethyl, difluoropropyl, 2-methylpropyl, butyl, cyanocyclopropyl, methylcyclopropyl, ethyl-cyclopropyl, dimethylcyclopropyl, trifluoromethylcyclopropyl, phenylcyclopropyl, fluorophenylcyclopropyl, hydroxycyclopropyl, aminocyclopropyl, cyclobutyl, trifluoromethylcyclobutyl, cyclohexyl, cyclohexylmethyl, phenyl, fluorophenyl, chlorophenyl, cyanophenyl, methylphenyl, hydroxyphenyl, methylsulfonylphenyl, dimethyl-sulfoxyiminylphenyl, benzyl, fluorobenzyl, difluorobenzyl, chlorobenzyl, (chloro)(fluoro)-benzyl, dichlorobenzyl, (chloro)(difluoro)benzyl, bromobenzyl, cyanobenzyl, methylbenzyl, Examples include dimethylbenzyl, trifluoromethylbenzyl, phenylbenzyl, hydroxybenzyl, hydroxymethylbenzyl, benzoyl, methoxybenzyl, dimethoxybenzyl, trifluoromethoxy-benzyl, methylsulfonylbenzyl, aminomethylbenzyl, aminoethylbenzyl, dimethylamino-benzyl, pyrrolidinylbenzyl, (dimethyl)(pyrrolidinyl)benzyl, morpholinylbenzyl, (dimethyl)(morpholinyl)benzyl, piperazinylbenzyl, acetylaminoethylbenzyl, phenylethyl, chlorophenylethyl, methylpyrazolyl, ethylpyrazolyl, isopropylpyrazolyl, (methyl)-(tetrahydropyranyl)pyrazolyl, methylisoxazolyl, ethylisoxazolyl, methyloxadiazolyl, ethyloxadiazolyl, cyclopropyloxadiazolyl, isopropyltriazolyl, pyridinyl, triazolylmethyl, benzotriazolylmethyl, pyridinylmethyl, and aminopyridinylmethyl.
[0190] R 6Preferred values include methylpyrazolyl, ethylpyrazolyl, isopropylpyrazolyl, methylisoxazolyl, ethylisoxazolyl, methyloxadiazolyl, ethyloxadiazolyl, cyclopropyloxadiazolyl, and isopropyltriazolyl.
[0191] R 6 Typical values include isopropylpyrazolyl, ethylisoxoxazolyl, methyl-oxadiazolyl, ethyloxadiazolyl, cyclopropyloxadiazolyl, and isopropyltriazolyl.
[0192] R 6 Selected values include methylpyrazolyl, ethylpyrazolyl, methyloxadiazolyl, and ethyloxadiazolyl.
[0193] R 6 Specific examples of selected values include methyloxadiazolyl and ethyloxadiazolyl. In the first embodiment, R 6 represents methyloxadiazolyl. In the second embodiment, R 6 This represents ethyloxadiazolyl, which may be substituted in some cases.
[0194] In general, R 6a is C 1-6 Represents alkyl, or R 6a is C 3-9 This represents a cycloalkyl group, which may optionally be substituted by one or more substituents.
[0195] In the first embodiment, R 6a is C 1-6 Represents alkyl. In the second embodiment, R 6a C is substituted in some cases. 3-9 Represents a cycloalkyl group. In the third embodiment, R 6a C is substituted in some cases. 3-7 This represents a heterocycloalkyl group.
[0196] Appropriately, R 6a is C 1-6 Represents alkyl, or R 6a represents cyclobutyl or oxetanyl, and either of these groups may optionally be substituted with one or more substituents.
[0197] Typically, R 6a is C 1-6 Represents alkyl, or R 6a represents cyclobutyl, which may optionally be substituted by one or more substituents.
[0198] R 6a Typical examples of the optional substituents above include halogens, cyanos, nitros, and C. 1-6 Alkyl, trifluoromethyl, hydroxy, hydroxy(C) 1-6 ) alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkylthio, C 1-6 Alkyl sulfinyl, C 1-6 Alkyl sulfonyl, amino, amino(C 1-6 ) Alkyl, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl and di(C 1-6 Examples include one, two, or three substituents independently selected from alkylaminosulfonyl compounds.
[0199] R 6aSuitable examples of the optional substituents mentioned above include one, two, or three substituents that can be selected independently of the halogen.
[0200] R 6a Typical examples of the above specific substituents include one, two, or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, trifluoromethylhydroxy, hydroxymethyl, oxo, methoxy, tert-butoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, aminomethyl, aminoethyl, methylamino, tert-butylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, and dimethylaminosulfonyl.
[0201] R 6a Preferred examples of the specific substituents mentioned above include one, two, or three substituents selected independently of fluoro.
[0202] R 6a Typical examples of specific values include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclobutyl, difluorocyclobutyl, and oxetanyl.
[0203] R 6a Exemplary examples of specific values include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclobutyl, and difluorocyclobutyl.
[0204] Typically, R 6a This represents cyclobutyl.
[0205] Typically, R 6brepresents hydrogen or methyl.
[0206] In the first embodiment, R 6b represents hydrogen. In the second embodiment, R 6b C 1-6 This represents alkyl, especially methyl.
[0207] Typically, R 6c represents hydrogen or methyl.
[0208] In the first embodiment, R 6c represents hydrogen. In the second embodiment, R 6c C 1-6 This represents alkyl, especially methyl.
[0209] Alternatively, partial-NR 6b R 6c This can preferably represent azetidine-1-yl, pyrrolidine-1-yl, oxazolidine-3-yl, isoxazolidine-2-yl, thiazolidin-3-yl, isothiazolidine-2-yl, piperidine-1-yl, morpholine-4-yl, thiomorpholine-4-yl, piperazine-1-yl, homopiperidine-1-yl, homomorpholine-4-yl, or homopiperazine-1-yl, and any of these groups may optionally be substituted with one or more substituents.
[0210] Complex ring part - NR 6b R 6c Selected examples of preferred substituents above include C 1-6 Alkyl, C 1-6 Alkylsulfonyl, hydroxy, hydroxy(C 1-6 ) alkyl, amino(C 1-6 ) Alkyl, cyano, oxo, C 2-6 Alkylcarbonyl, Carboxylate, C 2-6 Alkoxycarbonyl, amino, C 2-6 Alkylcarbonyl-amino, C 2-6 Alkylcarbonylamino(C 1-6 ) Alkyl, C 2-6 Alkoxycarbonylamino, C1-6 Examples include alkylsulfonyl-amino and aminocarbonyl compounds.
[0211] Complex ring part - NR 6b R 6c Selected examples of the above specific substituents include methyl, methylsulfonyl, hydroxy, hydroxymethyl, aminomethyl, cyano, oxo, acetyl, carboxy, ethoxycarbonyl, amino, acetylamino, acetylaminomethyl, tert-butoxycarbonylamino, methylsulfonylamino, and aminocarbonyl.
[0212] In general, R 7 -COR 7a , -CO2R 7a , or -SO2R 7b Represents, or R 7 represents hydrogen, or R 7 is C 1-6 Alkyl or C 3-9 This represents a cycloalkyl group, where any of these groups may optionally be substituted with one or more fluorine atoms.
[0213] For more details, see R 7 -COR 7a , -CO2R 7a , or -SO2R 7b Represents, or R 7 represents hydrogen, or R 7 is C 1-6 This represents an alkyl group, which may optionally be substituted with one or more fluorine atoms, generally one, two, or three fluorine atoms, typically two fluorine atoms.
[0214] Typically, R 7 is C 3-7 This represents a heterocycloalkyl group, which may optionally be substituted with one or more fluorine atoms.
[0215] Preferably, R 7 -CO2R 7a It represents.
[0216] In the first embodiment, R 7 ha-COR 7a This represents R. In the second embodiment, R 7 -CO2R 7a This represents R. In the third embodiment, R 7 -CO2R 7a This represents R. In the fourth embodiment, R 7 represents hydrogen. In the fifth embodiment, R 7 C is optionally substituted by one or more fluorine atoms, typically one, two, or three fluorine atoms. 1-6 Represents an alkyl group. In one embodiment of this, R 7 is unsubstituted C 1-6 R represents alkyl, particularly methyl or ethyl. In another embodiment of the present invention, R 7 C is a carbon atom substituted with one, two, or three fluorine atoms, typically two fluorine atoms. 1-6 It represents an alkyl group. An example of this embodiment is difluoroethyl. In the sixth embodiment, R 7 C is optionally substituted by one or more fluorine atoms, typically one, two, or three fluorine atoms. 3-9 Represents a cycloalkyl group. In one embodiment, R 7 is unsubstituted C 3-9 This represents cycloalkyl, particularly cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In another embodiment of the embodiment, R 7 C is a carbon atom substituted with one, two, or three fluorine atoms, typically two fluorine atoms. 3-9 This represents a cycloalkyl group. An example of this embodiment is difluorocyclobutyl. In the seventh embodiment, R 7 C is optionally substituted by one or more fluorine atoms, typically one, two, or three fluorine atoms. 3-7 Represents a heterocycloalkyl group. In one embodiment, R 7 is unsubstituted C 3-7 This represents heterocycloalkyl, particularly oxetanyl. In another embodiment of this embodiment, R7 C is substituted with one, two, or three fluorine atoms, typically two fluorine atoms. 3-7 This represents a heterocycloalkyl group.
[0217] R 7 One specific value is oxetanil.
[0218] Typically, R 7a C is optionally substituted with one, two, or three fluorine atoms. 1-6 Represents alkyl.
[0219] Preferably, R 7a C 1-6 Alkyl or difluoro(C) 1-6 ) Represents alkyl.
[0220] In the first embodiment, R 7a C 1-6 Represents alkyl, particularly methyl or ethyl. In the first embodiment of the present invention, R 7a represents methyl. In a second embodiment of the embodiment, R 7a represents ethyl. In the second embodiment, R 7a is difluoro(C 1-6 )-Alkyl, especially difluoroethyl.
[0221] R 7a Specific values include methyl and difluoroethyl.
[0222] Preferably, R 7b R represents methyl or ethyl. In the first embodiment, R 7b represents methyl. In the second embodiment, R 7b represents ethyl.
[0223] Preferably, R 8 R represents methyl or ethyl. In the first embodiment, R 8 represents methyl. In the second embodiment, R 8 represents ethyl.
[0224] Various subclasses of the compounds according to the present invention are represented by the compounds of formula (IIA-1), (IIA-2), (IIB-1), and (IIB-2) and their N-oxides, as well as their pharmaceutically acceptable salts: [ka] [ka] During the ceremony, X represents CH or N; R 16 is represented by methyl, ethyl, isopropyl, or cyclopropyl; and A is as defined above.
[0225] In the first embodiment, X represents CH. In the second embodiment, X represents N.
[0226] In the first embodiment, R 16 represents methyl. In the second embodiment, R 16 represents ethyl. In the third embodiment, R 16 represents isopropyl. In the fourth embodiment, R 16 This represents cyclopropyl.
[0227] Typically, R 16 This represents methyl, ethyl, or cyclopropyl.
[0228] Preferably, R 16 This represents methyl or ethyl.
[0229] Specific novel compounds according to the present invention include each of the compounds described in the attached examples, as well as their pharmaceutically acceptable salts and solvates.
[0230] The compounds according to the present invention are beneficial for the treatment and / or prevention of various human diseases, including inflammatory disorders and autoimmune disorders.
[0231] The compounds according to the present invention are useful for treating and / or preventing pathological disorders mediated by or associated with increased levels of pro-inflammatory IL-17 cytokines. Generally, pathological conditions include infections (viruses, bacteria, fungi, and parasites), infection-related endotoxin shock, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airway disease (COAD), chronic obstructive pulmonary disease (COPD), acute lung injury, pelvic inflammatory disease, Alzheimer's disease, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, ulcerative colitis, Castleman disease, axial spondyloarthritis, ankylosing spondylitis and other spondyloarthritis, dermatomyositis, myocarditis, uveitis, exophthalmos, autoimmune thyroiditis, Peyronie's disease, celiac disease, gallbladder disease, folliculitis, peritonitis, psoriasis, atopic dermatitis, hidradenitis suppurativa, vasculitis, surgical adhesions, stroke, and autoimmune diabetes. The following conditions are selected from the group consisting of type 1 diabetes, Lyme arthritis, meningoencephalitis, immune-mediated inflammatory diseases of the central and peripheral nervous systems, e.g., multiple sclerosis and Guillain-Barré syndrome, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, fibrotic disorders, e.g., pulmonary fibrosis, hepatic fibrosis, renal fibrosis, scleroderma, or systemic sclerosis, cancer (both solid tumors such as melanoma, hepatoblastoma, sarcoma, squamous cell carcinoma, transitional cell carcinoma, ovarian cancer, etc., and hematological malignancies, particularly acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, gastric cancer, and colon cancer), heart diseases including ischemic diseases such as myocardial infarction and atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, periodontitis, hypochlorhydria, and pain (especially pain associated with inflammation).
[0232] International Publication No. 2009 / 089036 demonstrates that modulators of IL-17 activity can be administered to inhibit or reduce the severity of ocular inflammatory disorders, particularly ocular surface inflammatory disorders including dry eye syndrome (DES). As a result, the compounds according to the present invention are useful for the treatment and / or prevention of IL-17-mediated ocular inflammatory disorders, particularly IL-17-mediated ocular surface inflammatory disorders including dry eye syndrome. Ocular surface inflammatory disorders include dry eye syndrome, full-thickness corneal transplantation, corneal transplantation, laminar or partial thickness transplantation, selective endothelial transplantation, corneal neovascularization, corneal prosthetic surgery, corneal surface inflammatory conditions, conjunctival scarring disorders, autoimmune conditions of the eye, bullous pemphigoid syndrome, Stevens-Johnson syndrome, ocular allergies, severe allergic (atopic) eye diseases, conjunctivitis, and microbial keratitis. Specific categories of dry eye syndrome include keratoconjunctivitis sicca (KCS), Sjögren's syndrome, Sjögren's syndrome-associated keratoconjunctivitis sicca, non-Sjögren's syndrome-associated keratoconjunctivitis sicca, keratitis sicca, dry eye syndrome, xerophthalmos, tear film dysfunction, decreased tear volume, lacrimal hypovolemia (ATD), meibomian gland dysfunction, and evaporation loss.
[0233] Exemplary examples, the compounds of the present invention may be useful in treating and / or preventing pathological disorders selected from the group consisting of arthritis, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airway disease, chronic obstructive pulmonary disease, atopic dermatitis, hidradenitis suppurativa, scleroderma, systemic sclerosis, pulmonary fibrosis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), axial spondyloarthritis, ankylosing spondylitis, and other spondyloarthritis, cancer, and pain (particularly pain associated with inflammation).
[0234] Preferably, the compounds of the present invention are useful for the treatment and / or prevention of psoriasis, psoriatic arthritis, hidradenitis suppurativa, axial spondyloarthritis, or ankylosing spondylitis.
[0235] The present invention also provides a pharmaceutical composition comprising the compound described above according to the present invention or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers.
[0236] The pharmaceutical composition according to the present invention can take the form of an oral, buccal, parenteral, nasal, topical, ocular, or rectal administration, or an administration by inhalation or blown-in.
[0237] For oral administration, pharmaceutical compositions may take the form of tablets, lozenges, or capsules prepared by conventional means using pharmaceutically acceptable excipients such as binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods well known in the art. Liquid formulations for oral administration may take the form of solutions, syrups, or suspensions, or may be provided as dry products to be mixed with water or other suitable vehicles before use. Such liquid formulations may be prepared by conventional means using pharmaceutically acceptable additives such as suspending agents, emulsifiers, non-aqueous vehicles, or preservatives. The preparations may also contain buffer salts, flavoring agents, coloring agents, or sweeteners, as needed.
[0238] Preparations for oral administration can be suitably formulated to provide controlled release of the active compound.
[0239] For buccal administration, the composition can take the form of tablets or lozenges formulated in the conventional manner.
[0240] The compounds according to the present invention can be formulated for parenteral administration by injection, for example, by bolus injection or infusion. The injectable formulations may be provided in unit dosage forms, for example, glass ampoules, or in multi-dose containers, for example, glass vials. The injectable compositions may take the form of suspensions, solutions, or emulsions in an oily or aqueous vehicle and may contain formulation agents such as suspending agents, stabilizers, preservatives, and / or dispersants. Alternatively, the active ingredient may be in powder form for preparation with a suitable vehicle before use, for example, sterile pyrogen-free water.
[0241] In addition to the formulations described above, the compounds according to the present invention can also be formulated as depot formulations. Such long-acting formulations can be administered by implantation or intramuscular injection.
[0242] For nasal or inhalation administration, the compounds according to the present invention can be conveniently delivered in the form of a pressurized pack or aerosol spray for nebulizers using a suitable propellant, such as dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gases or mixtures of gases.
[0243] The composition may be provided in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient, if desired. The pack or dispenser device may be accompanied by instructions for administration.
[0244] For topical administration, the compounds according to the present invention can be conveniently formulated into suitable ointments containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Specific carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax, and water. Alternatively, the compounds according to the present invention can be formulated into suitable lotions containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Specific carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol, and water.
[0245] For ocular administration, the compounds according to the present invention can be conveniently formulated as micronized suspensions in isotonic pH-adjusted sterile physiological saline, with or without a bactericidal or antifungal agent, such as phenylmercury nitrate, benzylalkonium chloride, or a preservative such as chlorhexidine acetate. Alternatively, for ocular administration, the compounds according to the present invention can be formulated as ointments such as petrolatum.
[0246] For rectal administration, the compounds according to the present invention can be conveniently formulated as suppositories. These can be prepared by mixing the active ingredient with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the active ingredient. Examples of such substances include cocoa butter, beeswax, and polyethylene glycol.
[0247] The amount of the compound according to the present invention required for the prevention or treatment of a particular condition varies depending on the compound selected and the condition of the patient being treated. However, generally, the daily dose may range from about 10 ng / kg to 1000 mg / kg, typically 100 ng / kg to 100 mg / kg, for example, about 0.01 mg / kg to 40 mg / kg body weight, for oral or buccal administration; from about 10 ng / kg to 50 mg / kg body weight for parenteral administration; and from about 0.05 mg to about 1000 mg, for example, about 0.5 mg to about 1000 mg, for nasal administration or by inhalation or inhalation.
[0248] If desired, the compounds according to the present invention may be administered co-administered with another pharmaceutically active agent, such as an anti-inflammatory molecule.
[0249] The compound of formula (I) above is of formula R 6 -CO2H can be prepared by a method comprising reacting the carboxylic acid with a compound of formula (III): [ka] In the formula, A, E, R 1a , R 1b and R 6 This is as defined above.
[0250] The reaction is conveniently achieved in the presence of a coupling agent and a base. Suitable coupling agents include 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphospholinane-2,4,6-trioxide. Suitable bases include organic amines, such as trialkylamines like N,N-diisopropylethylamine; or pyridines. The reaction is conveniently carried out at ambient temperature or high temperature in a suitable solvent, such as a cyclic ether like tetrahydrofuran; or a bipolar aprotic solvent like N,N-dimethylformamide or N,N-dimethylacetamide; or a chlorinated solvent like dichloromethane; or an organic ester solvent like ethyl acetate.
[0251] Alternatively, the reaction can be conveniently achieved in the presence of a coupling agent such as N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC). The reaction is preferably carried out in a suitable solvent, such as an organic nitrile solvent such as acetonitrile, at a suitable temperature, for example, in the range of 0°C.
[0252] R 6 C 1-6 When representing alkyl, for example methyl, the compound of formula (I) above is formula R 6 The compound can be prepared by a method comprising reacting a -COCl compound, such as acetyl chloride, with the compound of formula (III) defined above. The reaction is conveniently achieved in the presence of a base. Suitable bases include organic amines, such as trialkylamines such as N,N-diisopropylethylamine. The reaction conveniently proceeds at ambient temperature in a suitable solvent, such as a cyclic ether such as tetrahydrofuran.
[0253] R 6 ga-OR 6a When representing, the compound of formula (I) above is (i) formula R 6aThe compound can be prepared by a two-step method comprising (i) reacting the -OH compound with N,N'-disuccinimidyl carbonate, ideally in the presence of a base, such as an organic amine such as triethylamine, and (ii) reacting the resulting substance with the compound of formula (III) defined above. Steps (i) and (ii) can be conveniently carried out at ambient temperature in a suitable solvent, such as a chlorinated solvent such as dichloromethane or an organic nitrile solvent such as acetonitrile.
[0254] The intermediate of formula (III) above is the N-protecting group R from the compound of formula (IV). P It can be prepared by removing: [ka] In the formula, A, E, R 1a , and R 1b As defined above, R P This represents an N-protecting group.
[0255] N-protecting group R P Preferably, this is tert-butoxycarbonyl (BOC), in which case its removal can be conveniently induced by treatment with an acid, such as a mineral acid like hydrochloric acid or an organic acid like trifluoroacetic acid.
[0256] Alternatively, the N-protecting group R P This may be benzyloxycarbonyl, in which case its removal can be conveniently induced by catalytic hydrogenation, typically by treatment with hydrogen gas or ammonium formate in the presence of a hydrogenation catalyst, such as palladium carbon or palladium carbon hydroxide. N-protecting group R P In the modification method where benzyloxycarbonyl is present, its removal can be caused by treatment with boron tribromide.
[0257] In another procedure, the compound of formula (I) above, in which A represents the group of formula (Ac), (i) The step of saponifying the compound of formula (V): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , and R 6 As defined above, Alk 1 C 1-4 Alkyl, for example, represents methyl, ethyl, or tert-butyl; (ii) Compound (III) and formula R 6 Regarding the reaction between CO2H and carboxylic acids, under the same conditions as above, the resulting carboxylic acid derivative and formula R 3 It can be prepared by a two-step method, which includes the reaction with a compound of -H.
[0258] Similarly, the intermediate of the above formula (IV) in which A represents the base of formula (Ac) is (i) The step of saponifying the compound of formula (VI): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , R P , and Alk 1 This is as defined above; (ii) Compound (III) and formula R 6 Regarding the reaction between CO2H and carboxylic acids, under the same conditions as above, the resulting carboxylic acid derivative and formula R 3 It can be prepared by a two-step method, which includes the reaction with a compound of -H.
[0259] Alk 1If represents methyl or ethyl, the saponification reaction in step (i) is generally caused by treatment with a base. Suitable bases include inorganic hydroxides, such as alkali metal hydroxides such as lithium hydroxide or sodium hydroxide. The reaction is carried out with water and a suitable organic solvent, such as a cyclic ether such as tetrahydrofuran or methanol. 1-4 This process can be conveniently carried out in an alkanol at ambient temperature or high temperature.
[0260] Alternatively, Alk 1 If represents tert-butyl, the saponification reaction in step (i) can generally be induced by treatment with an acid, such as an organic acid such as trifluoroacetic acid. The reaction can conveniently proceed at ambient temperature in a suitable organic solvent, such as a chlorinating solvent such as dichloromethane.
[0261] An alternative coupling agent that may be usefully used in step (ii) is 2-chloro-1-methylpyridinium iodide.
[0262] The intermediate of formula (V) above is compound (III) and formula R 6 For the reaction between -CO2H and carboxylic acids, under the same conditions as above, formula R 6 -CO2H can be prepared by reacting the carboxylic acid with the compound of formula (VII): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , R 6 and Alk 1 This is as defined above.
[0263] The intermediate of formula (VII) above is formed from the N-protecting group R from the compound of formula (IV). P Regarding the removal of the N-protecting group R under the same conditions as above, the compound of formula (VI) defined above can be removed. PIt can be prepared by removing [something].
[0264] The intermediate of formula (VI) above can be prepared by reacting the compound of formula (VIII) with the compound of formula (IX): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b Alk 1 , and R P As defined above, L 1 This represents a suitable leaving group.
[0265] Leaving group L 1 These are typically halogen atoms, such as bromo.
[0266] The reaction is typically carried out in the presence of a base. Preferably, the base may be an inorganic base, such as a bicarbonate such as sodium bicarbonate, or an organic base such as pyridine. The reaction is carried out in a suitable solvent, such as isopropanol. 1-4 This is conveniently induced at high temperatures in alkanols or cyclic ethers such as 1,4-dioxane.
[0267] In another procedure, the compound of formula (I) above, in which A represents the group of formula (Aa) or (Ab), is compound (III) and formula R 6 Regarding the reaction between -CO2H and carboxylic acid under the same conditions as above, formula R 2 -CO2H can be prepared by a method comprising the step of reacting the carboxylic acid of formula (X) with a compound of formula (X): [ka] During the ceremony, A 1 represents the base of equation (Aa-1) or (Ab-1): [ka] In the formula, an asterisk (*) represents a bond point with the rest of the molecule; E, Y, R 1a , R 1b , R 2 , and R 6 This is as defined above.
[0268] The intermediate of formula (X) above is the N-protecting group R from the compound of formula (XI). z It can be prepared by removing: [ka] During the ceremony, A 2 represents the base of equation (Aa-2) or (Ab-2): [ka] In the formula, an asterisk (*) represents a bond point with the rest of the molecule; R z represents an N-protecting group; E, Y, R 1a , R 1b , and R 6 This is as defined above.
[0269] N-protecting group R z Preferably, this is tert-butoxycarbonyl (BOC), in which case its removal can be conveniently induced by treatment with an acid, such as a mineral acid like hydrochloric acid or an organic acid like trifluoroacetic acid.
[0270] The intermediate of the above equation (XI) is obtained in the following steps: (i) Under the same conditions as above, the N-protecting group R from the compound of formula (XII) P Removal of: [ka] In the formula, E, A 2 , R 1a , R 1b , and R P This is as defined above; (ii) Compound (III) and formula R 6 Regarding the reaction between CO2H and carboxylic acid under the same conditions as above, the substance obtained therefrom and formula R 6 - Reaction of CO2H with carboxylic acid It can be prepared by a two-step procedure, including [the following].
[0271] The intermediate of the above formula (XII) is obtained in the presence of a transition metal catalyst, as shown in formula A 2 -CO2H compounds can be prepared by reacting them with the compound of formula (XIII): [ka] In the formula, E, A 2 , R 1a , R 1b , and R P As defined above, L 2 This represents a suitable leaving group.
[0272] Leaving group L 2 Preferably, this is a halogen atom, such as chloro or bromo.
[0273] Suitable transition metal catalysts used in the reaction include [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine-N1,N1']bis-{3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C}iridium(III) hexafluorophosphate. The reaction is generally carried out in the presence of nickel(II) chloride ethylene glycol dimethyl ether complex and 4,4'-di-tert-butyl-2,2'-dipyridyl. The reaction is preferably induced in the presence of a base, such as an organic base like 1,8-diazabicyclo[5.4.0]undeca-7-ene, or an inorganic base like cesium carbonate, and the reactants are typically exposed to a bright light source. A suitable bright light source typically comprises an "integrated photoreactor" as described in ACS Cent.Sci.,2017,3,647-653. The reaction can be conveniently carried out at ambient temperature in a suitable solvent, such as a bipolar aprotic solvent like N,N-dimethylformamide.
[0274] The intermediate of formula (XIII) above can be prepared by reacting the compound of formula (IX) defined above with the compound of formula (XIV) under the same conditions as described above for the reaction between compound (VIII) and compound (IX): [ka] In the formula, R 1a , R 1b , and L 2 This is as defined above.
[0275] Alternatively, the intermediate of formula (XII) above can be prepared by reacting the compound of formula (IX) defined above with the compound of formula (VIIIA) under the same conditions as described above for the reaction between compound (VIII) and compound (IX): [ka] In the formula, A 2 , R 1a , and R1b This is as defined above.
[0276] The intermediate of the above formula (VIIIA) is compound (XIII) and formula A 2 Regarding the reaction with the compound -CO2H, under the same conditions as above, formula A 2 -CO2H compounds can be prepared by reacting them with the compound of formula (XIV) defined above.
[0277] In another procedure, as defined above, A represents the base of formula (Ad), and Z represents the base of formula (Zt) (where R 2z (where represents hydrogen), the compound of formula (I) is of formula R 1z -NH2 compounds and trialkyl orthoformate HCl (O-Alk 1 )3 can be prepared by a method comprising the step of reacting it with a compound of formula (XV): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , R 6 , R 1z , and Alk 1 This is as defined above.
[0278] The reaction conveniently proceeds at high temperatures in the presence of acetic acid. Typically, the reaction can be carried out in a suitable solvent, such as a cyclic ether like 1,4-dioxane.
[0279] The intermediate of formula (XV) above can be prepared by reacting the compound of formula (V) defined above with hydrazine hydrate.
[0280] The reaction is carried out in a suitable solvent, such as ethanol. 1-4 This process conveniently occurs at high temperatures within alkanol.
[0281] As defined above, the intermediate of the above formula (IV), where A represents the base of formula (Ad) and Z represents the base of formula (Zu), is obtained in the following steps: (i) Saponification of the compound of formula (VI) defined above by treatment with a base, (ii) Compound (III) and formula R 6 Regarding the reaction between -CO2H and a carboxylic acid, under the same conditions as above, the reaction of the resulting carboxylic acid derivative with the compound of formula (XVI) is also described. [ka] In the formula, R 2z As defined above, (iii) The obtained substance can be prepared by a three-step procedure including treatment with triphenylphosphine in the presence of a base, and cyclization of the obtained substance.
[0282] The saponification reaction in step (i) is generally caused by treatment with a base. Suitable bases include inorganic hydroxides, such as alkali metal hydroxides like lithium hydroxide.
[0283] Suitable bases for use in step (iii) include organic amines, such as trialkylamines such as triethylamine. The reaction conveniently proceeds at ambient temperature in the presence of hexachloroethane and a suitable solvent, such as a cyclic ether such as tetrahydrofuran.
[0284] In another procedure, A represents the base of formula (Ad), and Z represents the base of formula (Zw) or (Zx) as defined above (where R 1z If (the element is not hydrogen), the compound of formula (I) is formed in the following steps: (i) The step of reacting an alkali metal azide with a compound of formula (XVII), [ka] In the formula, E, R 1a , R1b , R 4a , R 4b , and R 6 This is as defined above; (ii) The obtained substance is given by formula R 1z -L 3 The step of reacting with the compound, and in the formula, R 1z L is as defined above (and is not hydrogen), 3 It can be prepared by a two-step procedure, which includes representing a suitable leaving group.
[0285] In step (i), the alkali metal azide is preferably sodium azide. The reaction is conveniently carried out at high temperature in the presence of ammonium chloride and a suitable solvent, such as a dipolar aprotic solvent such as N,N-dimethylformamide.
[0286] Leaving group L 3 Preferably, the derivative may be a sulfonyloxy derivative, such as trifluoromethanesulfonyloxy.
[0287] Step (ii) is generally achieved in the presence of a base. Suitable bases include alkali metal carbonates, such as potassium carbonate. The reaction is conveniently carried out at high temperatures in a suitable solvent, such as a carbonyl-containing solvent like acetone.
[0288] The intermediate of the above equation (XVII) is obtained in the following steps: (i) A step of reacting the compound of formula (XIII) defined above with ammonia, (ii) The substance obtained thereby can be prepared by a two-step procedure comprising the step of reacting the obtained substance with trifluoroacetic anhydride in the presence of pyridine.
[0289] Step (i) is to use a suitable solvent, such as methanol. 1-4 This process conveniently occurs at high temperatures within alkanol.
[0290] Step (ii) is conveniently carried out at ambient temperature in a suitable solvent, for example, a cyclic ether such as 1,4-dioxane.
[0291] A represents the base of formula (Ad), and Z represents the base of formula (Zq) defined above (wherein R 2z (where is hydrogen), the intermediate of formula (IV) above is given by formula R in the presence of a transition metal catalyst. 1z -N3 azide derivatives can be prepared by reacting them with compounds of formula (XVIII), [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , R 1z , and R P This is as defined above.
[0292] A suitable transition metal catalyst for use in the above reaction is chloro-(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II).
[0293] The reaction is conveniently carried out at high temperatures in a suitable solvent or mixture of solvents. Typical solvents include alkyl ethers, e.g., tert-butyl methyl ether or 1,2-dimethoxyethane; and cyclic ethers, e.g., tetrahydrofuran.
[0294] The intermediate of formula (XVIII) above can be prepared by reacting the compound of formula (XIX) with dimethyl(1-diazo-2-oxopropyl)phosphonate. [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , and R P This is as defined above.
[0295] The reaction generally takes place in the presence of a base. Preferably, the base may be an alkali metal carbonate, such as potassium carbonate. The reaction conveniently proceeds at ambient temperature in a suitable solvent or mixture of solvents. Typical solvents include C 1-4 Examples include alkanols, such as methanol; and chlorinated solvents, such as dichloromethane.
[0296] The intermediates of the above equation (XIX) are as follows: (i) O-protecting group R from compound of formula (XX) s Removal of: [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , and R P As defined above, R s This represents an O-protecting group; (ii) The compound obtained thereby can be prepared by a two-step procedure, which includes treatment with an oxidizing agent.
[0297] O-protecting group R s Preferably, it is acetyl.
[0298] R s If represents acetyl, its removal in step (i) above can be conveniently induced by treatment with a base. Preferably, the base may be an alkali metal carbonate, such as potassium carbonate. The reaction is carried out in a suitable solvent, such as methanol. 1-4 In alkanols, this is conveniently triggered by ambient temperature.
[0299] A suitable oxidizing agent for use in step (ii) above is 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess Martinperiodinane). The reaction is conveniently carried out at ambient temperature in a suitable solvent, such as a chlorinating solvent like dichloromethane.
[0300] Alternatively, the oxidizing agent used in step (ii) above may include a sulfur trioxide pyridine complex, in which case the reaction can be conveniently achieved in the presence of a base. Preferably, the base may be an organic amine, such as N,N-diisopropylethylamine.
[0301] The intermediate of formula (XX) above can be prepared by reacting the compound of formula (IX) defined above with the compound of formula (XXI) under the same conditions as described above for the reaction between compound (VIII) and compound (IX): [ka] In the formula, R 1a , R 1b , R 4a , R 4b and R s This is as defined above.
[0302] The intermediate of formula (IV) above, where A represents the group of formula (Ad) and Z represents the group of formula (Zw) defined above, can be prepared by reacting azidotrimethylsilane with the compound of formula (XXII): [ka] In the formula, E, R 1a , R 1b , R 4a , R 4b , R 1z , and R P This is as defined above.
[0303] The reaction is generally achieved in the presence of triphenylphosphine and an azodicarboxylate ester, for example, diisopropyl azodicarboxylate (DIAD). The reaction is conveniently initiated at ambient temperature in a suitable solvent, for example, a cyclic ether such as tetrahydrofuran.
[0304] The intermediate of formula (XXII) above is (i) saponification of the compound of formula (VI) as defined above by treatment with a base, and (ii) reaction of the carboxylic acid derivative thus obtained with a compound of formula R 6 -CO2H under the same conditions as those described above for the reaction between the compound (III) and the carboxylic acid of formula R 1z -NH2, and (iii) treatment of the carboxamide derivative thus obtained with Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane 2,4-disulfide), and can be prepared by a three-step method including.
[0305] The saponification reaction in step (i) is generally caused by treatment with a base. Suitable bases include inorganic hydroxides, for example, alkali metal hydroxides such as lithium hydroxide.
[0306] Step (iii) is conveniently carried out at elevated temperature in a suitable solvent, for example, a cyclic ether such as 1,4-dioxane.
[0307] In another procedure, when A represents a group of formula (Ae) (where Y represents N-R 7 and R 7 represents -COR 7a ), the compound of formula (I) above is prepared by a method including the step of reacting a carboxylic acid of formula R 6 -CO2H with a compound of formula (XXIII) under the same conditions as those described above for the reaction between the compound (III) and the carboxylic acid of formula R A carboxylic acid of formula R 7a -CO2H can be prepared by a method including reacting with a compound of formula (XXIII): [Chemistry] In the formula, A 11 represents the group of formula (Ae-1): [Chemistry] In the formula, the asterisk (*) represents the bonding point with the remaining part of the molecule; E, R 1a , R 1b , R 2 , and R 6 are as defined above.
[0308] Similarly, when A represents the group of formula (Ae) (where Y represents N-R 7 and R 7 represents -COR 7a ), the intermediate of the above formula (IV) can be prepared by reacting the carboxylic acid of compound (III) with the carboxylic acid of formula R 6 -CO2H under the same conditions as above, by reacting the carboxylic acid of formula R 7a -CO2H with the compound of formula (XXIV): [Chemistry] In the formula, E, A 11 [[ID=5l]], R 1a , R 1b , and R P are as defined above.
[0309] When A represents the group of formula (Ae) (where Y represents N-R 7 and R 7 represents -CO2R 7a ), the compound of the above formula (I) can be prepared by a method including reacting the compound of formula (XXIII) defined above with the compound of formula L 4a -CO2R 7a , where L 4a represents a suitable leaving group and R 7a is as defined above.
[0310] Similarly, A represents the base of equation (Ae) (where Y is NR). 7 Represents and R 7 -CO2R 7a (represented by) the intermediate of formula (IV) above is the compound of formula (XXIV) defined above, which is formula L 4a -CO2R 7a It can be prepared by reacting with a compound, where L 4a and R 7a This is as defined above.
[0311] Leaving group L 4a Preferably, this is a halogen atom, such as chloro. Alternatively, a leaving group L 4a Preferably, this may be 2,5-dioxopyrrolidine-1-yloxy.
[0312] The reaction is conveniently achieved in the presence of a base. Suitable bases include organic amines, such as trialkylamines like N,N-diisopropylethylamine or triethylamine. The reaction conveniently proceeds at ambient temperature in a suitable solvent, such as a chlorinated solvent like dichloromethane.
[0313] A represents the base of equation (Ae) (where Y is NR). 7 Represents and R 7 ga-SO2R 7b (represented by) the compound of formula (I) above is the compound of formula (XXIII) defined above, which is the compound of formula L 4b -SO2R 7b It can be prepared by a method comprising the step of reacting with a compound, where L 4b R represents a suitable leaving group. 7b This is as defined above.
[0314] Similarly, A represents the base of equation (Ae) (where Y is NR). 7 Represents and R 7 ga-SO2R 7b(represented by) the intermediate of formula (IV) above is the compound of formula (XXIV) defined above, which is formula L 4b -SO2R 7b It can be prepared by reacting with a compound, where L 4b and R 7b This is as defined above.
[0315] Leaving group L 4b Preferably, this is a halogen atom, such as chloroform.
[0316] The reaction is conveniently achieved in the presence of a base. Suitable bases include organic amines, such as trialkylamines like N,N-diisopropylethylamine or triethylamine. The reaction conveniently proceeds at ambient temperature in a suitable solvent, such as a chlorinated solvent like dichloromethane.
[0317] A represents the base of equation (Ae) (where Y is NR). 7 Represents and R 7 However, C is optionally substituted by one or more fluorine atoms. 1-6 (representing alkyl), the compound of formula (I) above is the compound of formula (XXIII) defined above, and formula L 5 -R 7c It can be prepared by a method comprising the step of reacting with a compound, where L 5 represents a suitable leaving group, and R 7c C is optionally substituted with one or more fluorine atoms. 1-6 Represents alkyl.
[0318] Similarly, A represents the base of equation (Ae) (where Y is NR). 7 Represents and R 7 However, C is optionally substituted by one or more fluorine atoms. 1-6 (representing alkyl), the intermediate of formula (IV) above is the compound of formula (XXIV) defined above, which is formula L 5 -R 7c It can be prepared by reacting with a compound, where L 5 and R7c is as defined above.
[0319] The leaving group L 5 is preferably a sulfonyloxy derivative, for example, trifluoro-methanesulfonyloxy.
[0320] The reaction is conveniently achieved in the presence of a base. Suitable bases include organic amines, such as trialkylamines like triethylamine. The reaction is conveniently carried out at ambient temperature in a suitable solvent, such as a chlorinated solvent like dichloromethane.
[0321] When A represents a group of formula (Ae) (where Y represents N-R 7 and R 7 represents C 3-9 cycloalkyl or C-bonded C 3-7 heterocycloalkyl (e.g., 3,3-difluoro-cyclobutyl or oxetan-3-yl) optionally substituted by one or more fluorine atoms), the compound of formula (I) above can be prepared by a method comprising reacting a compound of formula (XXIII) as defined above with a suitable cycloalkanone or heterocycloalkanone (e.g., 3,3-difluorocyclobutanone or oxetan-3-one) optionally substituted by one or more fluorine atoms in the presence of a reducing agent.
[0322] Similarly, when A represents a group of formula (Ae) (where Y represents N-R <b 7 and R 7 represents C 3-9 cycloalkyl or C-bonded C 3-7The intermediate of formula (IV) above, which represents a heterocycloalkyl (e.g., 3,3-difluorocyclobutyl or oxetan-3-yl), can be prepared by reacting the compound of formula (XXIV) defined above with a suitable cycloalkanone or heterocycloalkanone (e.g., 3,3-difluorocyclobutanone or oxetan-3-one), optionally substituted with one or more fluorine atoms, in the presence of a reducing agent.
[0323] The reducing agent is preferably sodium triacetoxyborohydride. The reaction proceeds conveniently in the presence of acetic acid.
[0324] As can be understood, the compound of formula (XXIII) above corresponds in itself to the compound of formula (I) defined above, where A represents the group of formula (Ae) (where Y is NR). 7 Represents and R 7 (This represents hydrogen.)
[0325] The compound of formula (XXIII) above can be conveniently prepared by reacting the corresponding compound of formula (I) with an acid, such as a mineral acid like hydrochloric acid, or an organic acid like trifluoroacetic acid, where A represents the group of formula (Ae), and Y represents NR 7 Represents (in the formula, R 7 -CO2R 7a Represents and R 7a (where represents tert-butyl).
[0326] Similarly, the intermediate of formula (XXIV) above can be conveniently prepared by reacting the corresponding compound of formula (IV) with an acid, such as a mineral acid like hydrochloric acid, or an organic acid like trifluoroacetic acid, where A represents the group of formula (Ae), and Y represents NR 7 Represents (in the formula, R 7 -CO2R 7a Represents and R 7a (where represents tert-butyl).
[0327] The intermediate of equation (IV) above, where A represents the base of equation (Ae), is formed by the following steps: (i) The step of saponifying the compound of formula (XXV): [ka] During the ceremony, A 12 represents the base of equation (Ae-2): [ka] In the formula, an asterisk (*) represents a bond point with the rest of the molecule; E, Y, R 1a , R 1b , R P , and Alk 1 This is as defined above; (ii) Compound (III) and formula R 6 Regarding the reaction between -CO2H and carboxylic acid, under the same conditions as above, the resulting carboxamide derivative and formula R 2 Reaction with -H compounds, (iii) It can be prepared by a three-step procedure, which includes the step of reducing the C=C double bond of the Y-containing ring.
[0328] The saponification reaction in step (i) is generally caused by treatment with a base. Suitable bases include inorganic hydroxides, such as alkali metal hydroxides such as lithium hydroxide or sodium hydroxide. Step (i) is performed with water and / or a suitable organic solvent, such as a cyclic ether such as tetrahydrofuran or methanol or ethanol. 1-4 In alkanols, this is conveniently triggered at ambient temperature or high temperatures.
[0329] An alternative coupling agent that may be usefully used in step (ii) is 2-chloro-1-methylpyridinium iodide.
[0330] The reduction of the C=C double bond in step (iii) can be conveniently induced by catalytic hydrogenation, typically by treatment with hydrogen gas or ammonium formate in the presence of a hydrogenation catalyst, such as palladium carbon or palladium carbon hydroxide.
[0331] The intermediate of the above formula (XXV) is obtained in the presence of a transition metal catalyst, as shown in formula A 12 -L 6 This compound can be prepared by reacting it with the compound of formula (XXVI): [ka] In the formula, M 1 L represents -B(OH)2, or its cyclic ester formed with an organic diol, such as pinacol, 1,3-propanediol, or neopentyl glycol. 6 represents a suitable leaving group, E, A 12 , R 1a , R 1b , and R P This is as defined above.
[0332] Leaving group L 6 The preferred element is a halogen atom, such as chloro or bromo. Alternatively, a leaving group L 6 Preferably, the derivative may be a sulfonyloxy derivative, such as methanesulfonyloxy or trifluoromethanesulfonyloxy.
[0333] The transition metal catalyst may preferably be tris(dibenzylideneacetone)-palladium(0), which may typically be used in combination with 2-dicyclohexyl-phosphino-2',4',6'-triisopropylbiphenyl (XPhos). Typically, the reaction is carried out at high temperature in the presence of potassium phosphate.
[0334] Alternatively, the transition metal catalyst may be [1,1'-bis(diphenylphosphin)-ferrocene]dichloropalladium(II). The reaction can be conveniently carried out at high temperatures in the presence of potassium carbonate.
[0335] Alternatively, the intermediate of formula (XXV) above can be compounded with compound (XXVI) and formula A in the presence of a transition metal catalyst. 12 -L 6 Regarding the reaction between the compound and the compound of formula A, under the same conditions as above, 12 -M 1 This compound can be prepared by reacting it with the compound of formula (XIII) defined above.
[0336] For example, M 1 The intermediate of formula (XXVI) above, in which represents a cyclic ester of -B(OH)2 formed with pinacol, can be prepared by reacting bis(pinacolato)diborone with the compound of formula (XIII) defined above in the presence of a transition metal catalyst.
[0337] Similarly, M 1 Formula A represents the cyclic ester of -B(OH)2 formed with pinacol. 12 -M 1 The intermediate is bis(pinacorato)diboron in the presence of a transition metal catalyst, as defined by formula A above. 12 -L 6 It can be prepared by reacting it with the compound.
[0338] The transition metal catalyst may preferably be tris(dibenzylideneacetone)-palladium(0), which may typically be used in combination with 2-dicyclohexyl-phosphino-2',4',6'-triisopropylbiphenyl (XPhos). Typically, the reaction is carried out at high temperature in the presence of potassium acetate.
[0339] If they are not commercially available, the starting materials of formulas (VIII), (IX), (XIV), (XVI), and (XXI) can be prepared by methods similar to those described in the accompanying examples, or by standard methods well known in the art.
[0340] It will be understood that any compound of formula (I) initially obtained from any of the above processes can, where appropriate, subsequently be synthesized into further compounds of formula (I) by techniques known in the art. For example, a compound containing an N-BOC moiety (BOC being an abbreviation for tert-butoxy-carbonyl) can be converted to the corresponding compound containing an NH moiety by treatment with an acid, such as a mineral acid like hydrochloric acid, or an organic acid like trifluoroacetic acid.
[0341] Compounds containing an NH functional group can typically be alkylated, for example, methylated, by treatment with a suitable alkyl halide, such as iodomethane, in the presence of a base, such as an inorganic carbonate such as sodium carbonate.
[0342] Compounds containing an NH functional group can typically be acylated, for example, acetylated, by treatment with a suitable acyl halogenate, such as acetyl chloride, in the presence of a base, such as an organic base such as N,N-diisopropylethylamine or triethylamine. Similarly, compounds containing an NH functional group can typically be acylated, for example, acetylated, by treatment with a suitable acyl anhydride, such as acetic anhydride, in the presence of a base, such as an organic base such as triethylamine.
[0343] Similarly, compounds containing an NH functional group typically exhibit appropriate C in the presence of a base, such as an organic base like triethylamine. 1-4 Treatment with an alkylsulfonyl chloride reagent, such as methylsulfonyl chloride, can remove NS(O)2Alk 1 Functional group (in the formula, Alk 1 This can be converted into the corresponding compound containing (as defined above).
[0344] Similarly, compounds containing an NH functional group can typically be converted to the corresponding compound containing a carbamate or urea moiety by treatment with a suitable chloroformic acid or carbamoyl chloride reagent in the presence of a base, such as an organic base such as triethylamine or N,N-diisopropylethylamine. Alternatively, compounds containing an NH functional group can typically be converted to the corresponding compound containing a urea moiety by treatment with a suitable amine-substituted (3-methylimidazole-3-ium-1-yl)methanone iodide derivative in the presence of a base, such as an organic base such as triethylamine. Alternatively, compounds containing an NH functional group can typically be converted to the corresponding compound containing a urea moiety by treatment with a suitable isocyanate derivative Alk in the presence of a base, such as an organic base such as triethylamine. 1 Treatment with -N=C=O results in the urea portion NC(O)N(H)Alk 1 (In the formula, Alk 1 This can be converted into the corresponding compound containing (as defined above).
[0345] Compounds containing an NH functional group can be converted to the corresponding compound containing an NC(H) functional group by treatment with an appropriate aldehyde or ketone in the presence of a reducing agent such as sodium triacetoxyborohydride.
[0346] C 1-4 Alkoxycarbonyl moiety -CO2Alk 1 (In the formula, Alk 1 Compounds containing the (as defined above) moiety can be converted to the corresponding compound containing the carboxylic acid (-CO2H) moiety by treatment with a base, such as an alkali metal hydroxide salt such as lithium hydroxide. Alternatively, compounds containing the tert-butoxy-carbonyl moiety can be converted to the corresponding compound containing the carboxylic acid (-CO2H) moiety by treatment with trifluoroacetic acid.
[0347] Compounds containing the carboxylic acid (-CO2H) moiety are compound (III) and formula R 6The reaction of -CO2H with a carboxylic acid can be converted to the corresponding compound containing the amide moiety by treatment with a suitable amine under similar conditions to those described above.
[0348] C 1-4 Alkoxycarbonyl moiety -CO2Alk 1 (In the formula, Alk 1 Compounds containing (as defined above) can be converted to the corresponding compound containing the hydroxymethyl (-CH2OH) moiety by treatment with a reducing agent such as lithium aluminum hydride.
[0349] C 1-4 Alkylcarbonyloxy portion - OC(O)Alk 1 (In the formula, Alk 1 Compounds containing (as defined above), such as acetoxy, can be converted to the corresponding compound containing the hydroxy(-OH) moiety by treatment with a base, such as an alkali metal hydroxide salt such as sodium hydroxide.
[0350] Compounds containing halogen atoms, such as bromos, can be converted to corresponding compounds optionally containing substituted aryl, heterocycloalkenyl, or heteroaryl moieties by treatment with appropriately substituted aryl, heterocycloalkenyl, or heteroarylboronic acid, or their cyclic esters, formed from organic diols, such as pinacol, 1,3-propanediol, or neopentyl glycol. The reaction is typically carried out in the presence of a transition metal catalyst and a base. The transition metal catalyst may be [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). Alternatively, the transition metal catalyst may be tris(dibenzylideneacetone)dipalladium(O), which may be advantageously used in combination with 2-dicyclohexyl-phosphino-2',4',6'-triisopropylbiphenyl (XPhos). Preferably, the base may be an inorganic base such as sodium carbonate or potassium carbonate.
[0351] Compounds containing halogen atoms, such as bromos, can be converted to corresponding compounds containing optionally substituted aryl or heteroaryl moieties by a two-step procedure comprising (i) a reaction with bis(pinacolato)diborone and (ii) a reaction of the compound obtained thereby with a suitably substituted bromoaryl or bromoheteroaryl derivative. Step (i) is conveniently induced in the presence of a transition metal catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) and potassium acetate. Step (ii) is conveniently induced in the presence of a transition metal catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) and an inorganic base such as sodium carbonate or potassium carbonate.
[0352] Compounds containing the cyano(-CN) moiety can be converted to the corresponding compound containing the 1-aminoethyl moiety by a two-step method comprising (i) a reaction with methylmagnesium chloride, ideally in the presence of titanium(IV) isopropoxide, and (ii) treatment of the resulting substance with a reducing agent such as sodium borohydride. If excess methylmagnesium chloride is used in step (i), the corresponding compound containing the 1-amino-1-methylethyl moiety can be obtained.
[0353] Compounds containing a partial -S- can be converted to the corresponding compound containing a partial -S(O)(NH)- by treatment with (diacetoxyiodo)benzene and ammonium carbamate.
[0354] Compounds containing a C=C double bond can be converted to corresponding compounds containing a CH-CH single bond by treatment with a hydrogenation catalyst, such as gaseous hydrogen in the presence of palladium-carbon.
[0355] Compounds containing aromatic nitrogen atoms can be converted to corresponding compounds containing an N-oxide moiety by treatment with a suitable oxidizing agent, such as 3-chloroperbenzoic acid.
[0356] If a mixture of products is obtained from any of the above methods for preparing compounds according to the present invention, the desired product can be separated therefrom at appropriate stages by preparative HPLC or conventional methods such as column chromatography utilizing silica and / or alumina in combination with a suitable solvent system.
[0357] If the above method for preparing the compound according to the present invention produces a mixture of stereoisomers, these isomers can be separated by the prior art. In particular, if it is desired to obtain a specific enantiomer of the compound of formula (I), this can be generated from the corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers. Thus, for example, a diastereomer derivative, e.g., a salt, can be generated by the reaction of a mixture of an enantiomer of formula (I), e.g., a racemate, with a suitable chiral compound, e.g., a chiral base. The diastereomer may then be separated by any convenient means, e.g., crystallization, and the desired enantiomer may be recovered, e.g., by treatment with acid if the diastereomer is a salt. In another resolution process, the racemate of formula (I) can be separated using chiral HPLC. Furthermore, if desired, a specific enantiomer can be obtained by using a suitable chiral intermediate in one of the above methods. Alternatively, specific enantiomers can be obtained by enantiomer-specific enzymatic biotransformation, for example, by ester hydrolysis using an esterase, followed by purification of only the enantiomerically pure hydrolyzed acid from the unreacted ester counterpart. Chromatography, recrystallization, and other conventional separation procedures can also be used with intermediates or final products to obtain the specific geometric isomers of the present invention.
[0358] During any of the above synthetic sequences, it may be necessary and / or desirable to protect any sensitive or reactive groups of the molecules involved. This can be achieved by conventional protecting groups, such as those described in Greene's Protective Groups in Organic Synthesis, edited by PGMWuts, John Wiley & Sons, 5, 2014. Protecting groups can be removed at any convenient subsequent step using methods known in the art.
[0359] The compounds according to the present invention potently inhibit IL-17-induced IL-6 release from human dermal fibroblasts. Therefore, when tested in the HDF cell line assay described below, the compounds of the present invention exhibit pIC of 5.0 or higher, generally 6.0 or higher, usually 7.0 or higher, typically 7.2 or higher, preferably 7.5 or higher, ideally 7.8 or higher, and preferably 8.0 or higher. 50 The value is shown (pIC 50 -log 10 [I C 50 ] is equal to IC 50 Since it is expressed as molar concentration, a person skilled in the art can determine a higher pIC 50 (You will understand that the higher the value, the more active the compound.)
[0360] Inhibition of IL-17A-induced IL-6 release from dermal fibroblast cell lines The purpose of this assay is to test the neutralizing ability of the IL-17 protein in primary human cell lines. While IL-17 alone stimulates normal human dermal fibroblasts (HDFs) with only a very weak signal, when combined with certain other cytokines such as TNFα, synergistic effects can be observed in the production of inflammatory cytokines, namely IL-6.
[0361] HDF was stimulated with IL-17A (50 pM) combined with TNF-α (25 pM). The resulting IL-6 response was then measured using a Cisbio homogeneous time-resolved FRET kit. The kit utilizes two monoclonal antibodies, one labeled with Eucryptate (donor) and the other with d2 or XL665 (acceptor). The signal intensity is proportional to the concentration of IL-6 present in the sample (the ratio is calculated as 665 / 620 × 10⁴).
[0362] This assay measures the ability of compounds to inhibit IL-17-induced IL-6 release from human dermal fibroblasts.
[0363] HDF cells (Sigma#106-05n) were cultured in complete medium (DMEM + 10% FCS + 2 mM L-glutamine) and maintained in tissue culture flasks using standard techniques. Cells were harvested from the tissue culture flasks on the morning of the assay using TrypLE (Invitrogen#12605036). TrypLE was neutralized with complete medium (45 mL), and the cells were centrifuged at 300 × g for 3 minutes. Cells were resuspended in complete medium (5 mL) and counted, yielding 3.125 × 10⁶ cells. 4 After adjusting the concentration to cells / mL, 40 μL / well was added to a 384-well assay plate (Corning #3701). The cells were left at 37°C / 5% CO2 for a minimum of 3 hours to allow them to adhere to the plate.
[0364] After serially diluting the compound with DMSO, the aqueous dilution was placed in a 384-well dilution plate (Greiner #781281), 5 μL from the titration plate was transferred to 45 μL of complete medium, and the mixture was obtained to obtain a solution containing 10% DMSO.
[0365] A mixture of TNFα and IL-17 cytokines was prepared in complete medium to a final concentration of TNFα 25 pM / IL-17A 50 pM, and then 30 μL of the solution was added to a 384-well reagent plate (Greiner #781281).
[0366] 10 μL from an aqueous dilution plate was transferred to a reagent plate containing 30 μL of diluted cytokine to obtain a 2.5% DMSO solution. The compound was incubated with the cytokine mixture at 37°C for 5 hours. After incubation, 10 μL was transferred to an assay plate to obtain a 0.5% DMSO solution, which was then incubated at 37°C / 5% CO2 for 18–20 hours.
[0367] Europium cryptotate and Alexa 665 from the Cisbio IL-6 FRET kit (Cisbio#62IL6PEB) were diluted in reconstitution buffer and mixed 1:1 according to the kit insert. 10 μL of the FRET reagent was added to a white, low-volume 384-well plate (Greiner#784075), and then 10 μL of the supernatant was transferred from the assay plate to the Greiner reagent plate. The mixture was incubated at room temperature for 3 hours with gentle shaking (<400 rpm), and then read using a Synergy Neo 2 plate reader (excitation: 330 nm; emission: 615 / 645 nm).
[0368] When tested with the HDF cell line assay described above, the example compound in the attached example yielded the following pIC values: 50 It was found that it shows a value. [Table 1]
[0369] The following examples illustrate the preparation of compounds according to the present invention.
[0370] example Abbreviation DCM: Dichloromethane THF: Tetrahydrofuran MeOH: methanol EtOH: Ethanol DMSO: Dimethyl sulfoxide DIPEA: N,N-diisopropylethylamine DMF: N,N-dimethylformamide DMA: N,N-dimethylacetamide æ:ethyl acetate TFA: Trifluoroacetic acid IPA: Isopropyl alcohol DMAP: 4-(dimethylamino)pyridine TBME: tert-butylmethyl ether LDA: Lithium diisopropylamide NBS: N-bromosuccinimide DIAD: Diisopropyl azodicarboxylate Xantphos:4,5-bis(diphenylphosphino)-9,9-dimethylxanthene T3P (registered trademark): Anhydrous propylphosphonic acid solution HATU:1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate {Ir[dF(CF3)ppy]2(dtbpy)}PF6:[4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine-N1,N1']bis-{3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C}iridium(III) hexafluorophosphate Lawson's Reagent: 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan 2,4-disulfide h: time rt: room temperature M: Mass; Moles RT: retention time HPLC: High-performance liquid chromatography LCMS: Liquid Chromatography Mass Spectrometry SFC: Supercritical Fluid Chromatography FCC: Flash Column Chromatography
[0371] Analysis and separation methods Method 1 X-Bridge C18 Waters 2.1×20mm, 2.5μm column Column temperature: 40℃ Mobile phase A: 10 mM ammonium formate in water + 0.1% ammonia solution Mobile phase B: Acetonitrile + 5% water + 0.1% ammonia solution Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 4.00 5.00 95.00 5.00 5.00 95.00 5.10 95.00 5.00
[0372] Method 2 Waters UPLC (Registered Trademark) BEH (Trademark) C18, Part Number 186002352, 2.1 × 100 mm, 1.7 μm column Column temperature: 40℃ Mobile phase A: 2 mM ammonium bicarbonate buffered at pH 10 Mobile phase B: Acetonitrile Gradient program flow rate 0.6 mL / min Time A% B% 0.00 95.00 5.00 5.30 0 100 5.80 0 100 5.82 95.00 5.00 7.00 95.00 5.00
[0373] Method 3 Phenomenex, Kinetex-XB C18, 2.1 mm × 100 mm, 1.7 μm column Column temperature: 40℃ Mobile phase A: 0.1% formic acid in water Mobile phase B: 0.1% formic acid in acetonitrile Gradient program: Flow rate 0.6 mL / min; Injection volume 1 μL Time A% B% 0.00 95 5 5.30 0 100 5.80 0 100 5.82 95 5 7.00 95 5 UV 215nm, PDA spectrum 200-400nm, step 1nm MSD scan positive 150-850
[0374] Method 4 X-Bridge C18 Waters 2.1×20mm, 2.5μm column Mobile phase A: 10 mM ammonium formate in water + 0.1% ammonia solution Mobile phase B: Acetonitrile + 5% water + 0.1% ammonia solution Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 1.50 5.00 95.00 2.25 5.00 95.00 2.50 95.00 5.00
[0375] Method 5 X-Bridge C18 Waters 2.1×20mm, 2.5μm column Column temperature: 40℃ Mobile phase A: 10 mM ammonium formate + 0.1% formic acid in water Mobile phase B: Acetonitrile + 5% water + 0.1% formic acid Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 1.50 5.00 95.00 2.25 5.00 95.00 2.50 95.00 5.00
[0376] Method 6 X-Bridge C18 Waters 2.1×20mm, 2.5μm column Column temperature: 40℃ Mobile phase A: 10 mM ammonium formate + 0.1% formic acid in water Mobile phase B: Acetonitrile + 5% water + 0.1% formic acid Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 4.00 5.00 95.00 5.00 5.00 95.00 5.10 95.00 5.00
[0377] Method 7 Phenomenex Gemini NX-C18 2×20mm, 3μm column Mobile phase A: 10 mM ammonium formate in water + 0.1% ammonia solution Mobile phase B: Acetonitrile + 5% water + 0.1% ammonia solution Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 4.00 5.00 95.00 5.00 5.00 95.00 5.10 95.00 5.00
[0378] Method 8 Waters Acquity UPLC BEH C18 2.1×50mm, 1.7μm column Mobile phase A: 10 mM ammonium formate in water + 0.1% ammonia solution Mobile phase B: Acetonitrile + 5% water + 0.1% ammonia solution Gradient program: Flow rate 1.5 mL / min Time A% B% 0.00 95.00 5.00 0.10 95.00 5.00 3.50 5.00 95.00 4.00 5.00 95.00 4.05 95.00 5.00
[0379] Method 9 Waters Sunfire C18 30×100mm, 10μm column Column temperature: Room temperature Mobile phase A: Water + 0.1% formic acid Mobile phase B: Acetonitrile + 0.1% Formic Acid Gradient program: Flow rate 40 mL / min Time A% B% 0.00 70 30 0.55 70 30 11.0 5 95 13.1 5 95 13.31 70 30
[0380] Method 10 Waters Acquity UPLC BEH C18 2.1×50mm, 1.7μm column Mobile phase A: 10 mM ammonium formate + 0.1% formic acid in water Mobile phase B: Acetonitrile + 5% water + 0.1% formic acid Gradient program: Flow rate 1.5 mL / min Time A% B% 0.00 95.00 5.00 0.10 95.00 5.00 3.50 5.00 95.00 4.00 5.00 95.00 4.05 95.00 5.00
[0381] Method 11 Phenomenex Gemini NX-C18 2×20mm, 3μm column Mobile phase A: 10 mM ammonium formate in water + 0.1% ammonia solution Mobile phase B: Acetonitrile + 5% water + 0.1% ammonia solution Gradient program: Flow rate 1 mL / min Time A% B% 0.00 95.00 5.00 1.50 5.00 95.00 2.25 5.00 95.00 2.50 95.00 5.00
[0382] Intermediate 1 tert-butyl N-(6-chloro-5-methylpyridazine-3-yl)carbamate To a stirred solution of 6-chloro-5-methylpyridazine-3-amine (4.21 g, 29.3 mmol) and DIPEA (20 mL, 0.117 mol) in DMF (45 mL), di-tert-butyl dicarbonate (14.55 g, 66.7 mmol) and DMAP (358 mg, 2.93 mmol) were successively added. The reaction mixture was stirred in rt for 3 hours and then concentrated to dryness under high vacuum. The resulting brown solid was dissolved in methanol (45 mL) and dipotassium carbonate (4.05 g, 29.3 mmol) was added. The reaction mixture was stirred in rt for 16 hours and then concentrated under vacuum, redissolved in ethyl acetate (250 mL), and washed with water (200 mL). The resulting suspension was filtered through a Celite® pad while washing with ethyl acetate (500 mL). The layers were separated, and the aqueous layer was re-extracted with ethyl acetate (2 × 50 mL). The combined organic phases were washed with brine (40 mL), then dried with sodium sulfate, and concentrated under vacuum. The resulting brown solid was purified by silica column chromatography eluting with 0-50% dimethyl phosphate in heptane to obtain the labeled compound (6.87 g, 79%) as a white solid.
number
[0383] Intermediate 2 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]acetic acid To a solution of intermediate 1 (5.02 g, 20.6 mmol) at -50°C in THF (60 mL), 2 M LDA (31 mL, 61.8 mmol) in THF / n-heptane / ethylbenzene was added dropwise. The reaction mixture was stirred at -50°C for 5 minutes, then slowly heated to -30°C and stirred for 20 minutes. Gaseous CO2 was bubbling into the reaction mixture (the internal temperature reached -10°C upon addition). The reaction mixture was cooled back to -50°C and stirred for a further 40 minutes, then diluted with saturated NH4Cl aqueous solution (20 mL) and ELISA (20 mL). The organic layer was discarded. The pH of the aqueous layer was adjusted to pH 3-4 using 2 M HCl aqueous solution. The resulting aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over sodium sulfate and concentrated under vacuum to obtain the marked compound (4.7 g, 62%) as an orange oil.
number
[0384] Intermediate 3 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]methyl acetate To a solution of intermediate 2 (79%, 4.70 g, 12.9 mmol) in methanol (40 mL), 1,4-dioxane with 4 M HCl (10 mL, 40.0 mmol) was added. The reaction mixture was stirred for 4 hours. The pH of the reaction mixture was adjusted to pH 7 using saturated NaHCO3 aqueous solution, and then water (100 mL) was added. The resulting solid precipitate was collected by vacuum filtration, washed with the minimum amount of water, and then dried in a vacuum oven at 40°C for 16 hours to obtain the marked compound (3.83 g, 93%) as a white solid.
number
[0385] Intermediate 4 Methyl 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]-4,4-difluorobuta-2-enoate To a solution of intermediate 3 (1.22 g, 4.04 mmol) in 1,4-dioxane (24 mL), triethylamine (1127 μL, 8.09 mmol) and 1-ethoxy-2,2-difluoroethanol (637 mg, 5.05 mmol) were added. The reaction mixture was heated at 102 °C for 3 hours. Further amounts of triethylamine (0.56 mL, 4.04 mmol) and 1-ethoxy-2,2-difluoroethanol (0.56 mL, 5.05 mmol) were added. The reaction mixture was heated at 102 °C for another 3 hours and then concentrated under vacuum. The resulting brown oil was purified by silica column chromatography eluting with 0-40% ethylethanol in heptane to obtain the marked compound (965 mg, 66%) as a white solid.
number
[0386] Intermediate 5 Methyl 2-(6-amino-3-chloropyridazine-4-yl)-4,4-difluorobuta-2-enoate Intermediate 4 (90%, 528 mg, 1.31 mmol) was stirred at rt for 2 hours in DCM (2.5 mL) and TFA (1.5 mL, 19.6 mmol). The reaction mixture was diluted with DCM (30 mL), washed with saturated NaHCO3 aqueous solution (2 × 10 mL) and brine (10 mL), then dried over sodium sulfate and concentrated under vacuum to obtain the marked compound (90% purity) (357 mg, 93%) as a yellow oil.
number
[0387] Intermediate 6 Methyl 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]-6-chloroimidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobuta-2-enoate Intermediate 5 (90%, 357 mg, 1.22 mmol) and benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (640 mg, 1.58 mmol) were stirred in dry 1,4-dioxane (5 mL), and 2,6-dimethylpyridine (369 μL, 3.17 mmol) was added. The reaction mixture was sealed and heated at 80°C for 3.5 hours. The residue was diluted with ethyl acetate (50 mL), washed with water (20 mL), saturated NH4Cl aqueous solution (20 mL), water (20 mL), and brine (20 mL), then dried over sodium sulfate and concentrated under vacuum. The substance was purified by silica column chromatography using a gradient of 0-100% ethyl acetate in heptane to obtain the marked compound (90% purity) (673 mg, 87%) as yellow / orange foam.
number
[0388] Intermediate 7 Methyl 2-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate Intermediate 6 (90%, 600 mg, 0.949 mmol) was dissolved in methanol (20 mL), and 1 M aqueous HCl (5.0 mL, 5.00 mmol) was added, followed by 10% Pd / C (50% wet) (5.0%, 202 mg, 0.0949 mmol). The reaction mixture was stirred under 1 atm of H2 for 2.5 hours, then filtered with Celite®, and concentrated under vacuum to remove most of the methanol. The residue was diluted with ethyl acetate (50 mL) and washed with saturated aqueous NaHCO3 (30 mL). The aqueous layer was further extracted with ethyl acetate (20 mL). The organic extracts were combined, washed with brine (20 mL), then dried over sodium sulfate, and concentrated under vacuum. The residue was purified by silica column chromatography eluting with a gradient of 0-90% MeOH in DCM to obtain the marked compound (95% purity) (260 mg, 65%) as orange oil.
number
[0389] Intermediate 8 Methyl 2-{2-[(S)-(tert-butoxycarbonylamino)(4,4-difluorocyclohexyl)methyl]imidazo-[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate Intermediate 7 (95%, 500 mg, 1.18 mmol) was dissolved in DCM (20 mL), and di-tert-butyl dicarbonate (309 mg, 1.42 mmol) was added. The reaction mixture was stirred in rt for 2.5 hours, then diluted with DCM (20 mL), washed with water (2 × 20 mL), dried over sodium sulfate, and concentrated under vacuum to obtain the marked compound (90% purity) (660 mg, 100%) as a brown foam.
number
[0390] Intermediate 9 2-{2-[(S)-(tert-butoxycarbonylamino)(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]-pyridazin-7-yl}-4,4-difluorobutanoic acid Intermediate 8 (90%, 660 mg, 1.18 mmol) was dissolved in water (5 mL), methanol (5 mL), and THF (5 mL). Lithium hydroxide hydrate (1:1:1) (198 mg, 4.73 mmol) was added, and the reaction mixture was stirred for 45 minutes, then concentrated under vacuum to remove most of the organic solvent. The remaining mixture was diluted with ethyl acetate (30 mL) and water (30 mL), and the aqueous portion was then adjusted to pH 5 using 1 M aqueous HCl (5 mL). The mixture was separated, and the aqueous layer was further extracted with ethyl acetate (30 mL). The combined organic extracts were dried over sodium sulfate and concentrated under vacuum to obtain the marked compound (95% purity) (610 mg, 100%) as a yellow foam.
number
[0391] Intermediate 10 tert-butyl N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethyl-carbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]carbamate Intermediate 9 (95%, 610 mg, 1.19 mmol) was dissolved in DMF (8 mL). 2,2,2-trifluoroethaneamine (0.10 mL, 1.30 mmol) and DIPEA (0.41 mL, 2.37 mmol) were added, followed by HATU (541 mg, 1.42 mmol). The reaction mixture was stirred in rt for 70 minutes, and then 2,2,2-trifluoroethaneamine (0.10 mL, 1.30 mmol) and HATU (150 mg, 0.39 mmol) were added. The reaction mixture was stirred for 20 minutes, then diluted with water (20 mL) and sonicated. The mixture was filtered, and the viscous solid was washed with a small amount of water. The solid was dissolved in ethyl acetate, then dried over sodium sulfate, and concentrated under vacuum to obtain the marked compound (90% purity) (753 mg, 100%) as an orange foam.
number
[0392] Intermediate 11 2-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluoro-N-(2,2,2-trifluoroethyl)butanamide Intermediate 10 (90%, 753 mg, 1.19 mmol) was stirred in DCM (7.5 mL) and TFA (2.5 mL) for 45 minutes, and then concentrated under vacuum. The residue was dissolved in DCM (50 mL), washed with saturated NaHCO3 aqueous solution (2 × 20 mL) and brine (20 mL), then dried over sodium sulfate, and concentrated under vacuum. The substance was purified by silica column chromatography eluting with a gradient of 0–10% MeOH in DCM to obtain the marked compound (364 mg, 65%) as a light brown solid.
number
[0393] Intermediate 12 Ethyl 2-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]-methyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorobutanoate HATU (161 mg, 0.423 mmol) was added at rt to a mixture of 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (54 mg, 0.423 mmol) and DIPEA (123 μL, 0.705 mmol) in DMF (3 mL). The reaction mixture was stirred at rt for 5 minutes, and then the solution of intermediate 21 (128 mg, 0.282 mmol) and DIPEA (123 μL, 0.705 mmol) in DMF (3 mL) was added. The reaction mixture was stirred at rt for 16 hours, and then diluted with HCl (50 mL) and washed with water (3 × 60 mL). The organic phase was dried over sodium sulfate and concentrated to dryness under vacuum. The crude residue was purified by silica column chromatography eluting with 10-60% HCl in heptane to obtain the marked compound (112 mg, 55%) as yellowish-brown rubber.
number
[0394] Intermediate 13 2-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]-methyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorobutanoic acid A mixture of lithium hydroxide monohydrate (20 mg, 0.468 mmol) and intermediate 12 (112 mg, 0.213 mmol) in THF (2.5 mL), water (0.4 mL), and methanol (1 mL) was stirred at rt for 16 hours. The reaction mixture was concentrated to a low volume under vacuum, diluted with RINKAN (50 mL), and then 0.5 M aqueous HCl was added until the pH reached 3. The layers were separated, and the aqueous layer was extracted with RINKAN (2 × 30 mL). The organic phase was washed with brine, dried over sodium sulfate, and then concentrated to dryness under vacuum to obtain the marked compound (90 mg, 82%) as a yellow solid.
number
[0395] Intermediate 14 tert-butyl N-[(1R)-2-methyl-1-(methylcarbamoyl)propyl]carbamate To a solution of N-(tert-butoxycarbonyl)-D-valine (1200 mg, 5.52 mmol) in DCM (25 mL), DIPEA (2.2 mL, 12.2 mmol) and (1H-benzotriazole-1-yloxy)[tris-(dimethylamino)]phosphonium hexafluorophosphate (2443 mg, 5.52 mmol) were added. Methylamine (2 M, 4.4 mL, 8.84 mmol) was added, and the solution was stirred for 18 hours. DCM (25 mL) was added, and the reaction mixture was washed with saturated NH4Cl aqueous solution (10 mL) and saturated NaHCO3 aqueous solution (10 mL), and then dried over magnesium sulfate. The solvent was removed. The resulting solid was purified by silica column chromatography eluting with 0-50% ethyl acetate in heptane, yielding the marked compound (1.32 g, 98%) as a white solid.
number
[0396] Intermediate 15 (2R)-2-amino-N,3-dimethylbutanamidetrifluoroacetate TFA (3 mL) was added to a solution of intermediate 14 (300 mg, 1.30 mmol) in DCM (3 mL). The reaction mixture was stirred for 1 hour. The solvent was removed, and the excess TFA was azeotropically removed with 1:1 DCM / heptane to obtain the marked compound (containing 50% TFA) (474 mg, 149%) as a pale yellow oil.
number
[0397] Intermediate 16 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]ethyl acetate HCl in 1,4-dioxane (4M, 4.6 mL, 18.6 mmol) was added at rt to a solution of intermediate 2 (3.56 g, 12.4 mmol) in ethanol (44.5 mL). The reaction mixture was stirred at rt for 22 hours, then diluted with HCl (100 mL) and washed with saturated NaHCO3 aqueous solution (30 mL). The aqueous phase was extracted with HCl (3 × 50 mL). The combined organic layers were dried over sodium sulfate, then filtered and concentrated to dryness. The residue was purified by silica column chromatography eluting with 10-30% HCl in heptane to obtain the marked compound (3.17 g, 81%) as an off-white solid.
number
[0398] Intermediate 17 Ethyl 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]-4,4-difluorobuta-2-enoate 1-Ethoxy-2,2-difluoroethanol (90%, 3.0 mL, 24.5 mmol) was added at rt-rate to a solution of intermediate 16 (1.55 g, 4.91 mmol) and triethylamine (2.7 mL, 19.6 mmol) in 1,4-dioxane (10 mL). The reaction mixture was stirred in a pressure round-bottom flask at 100°C for 16 hours, and then concentrated to dryness. The residue was purified by silica column chromatography eluted with 10-20% ethylethanol in heptane to obtain the marked compound (1.39 g, 62%) as yellow rubber.
number
[0399] Intermediate 18 Ethyl 2-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]-4,4-difluorobutanoate Sodium borohydride (27 mg, 0.719 mmol) was added at -4°C to a solution of intermediate 17 (255 mg, 0.675 mmol) in DCM (3.5 mL), followed by the addition of ethanol (3.5 mL). The reaction mixture was maintained at -4°C for 15 minutes with stirring. Saturated NH4Cl aqueous solution (30 mL) was added, and the reaction mixture was stirred at -4°C for 15 minutes, followed by dilution with water (30 mL) and DCM (60 mL). The layers were separated, and the aqueous layer was extracted with DCM (2 × 30 mL). The combined organic phases were filtered through a phase separation filter, and then concentrated to dryness under vacuum to obtain the marked compound (261 mg, 83%) as pale yellow rubber.
number
[0400] Intermediate 19 Ethyl 2-(6-amino-3-chloropyridazine-4-yl)-4,4-difluorobutanoate TFA (1.1 mL, 14.4 mmol) was added at rt to a solution of intermediate 18 (281 mg, 0.741 mmol) in DCM (1.1 mL). The reaction mixture was stirred at rt for 3 hours, then diluted with DCM (10 mL), and saturated NaHCO3 aqueous solution (10 mL) was added. The layers were separated, and the aqueous phase was re-extracted with DCM (2 × 10 mL). The organic phase was dried over sodium sulfate, then concentrated to dryness under vacuum to obtain the marked compound (207 mg, 86%) as yellowish-brown rubber.
number
[0401] Intermediate 20 Ethyl 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]-6-chloroimidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate 2,6-dimethylpyridine (220 μL, 1.89 mmol) was added to a stirred mixture of intermediate 19 (203 mg, 0.726 mmol) and benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (381 mg, 0.944 mmol) in 1,4-dioxane (2.9 mL). The reaction mixture was stirred in a pressure vial at 80°C for 4 hours. The residue was diluted with ethyl acetate (50 mL), washed with water (20 mL) and brine (10 mL), then dried over sodium sulfate and concentrated to dryness under vacuum. The crude residue was purified by silica column chromatography eluting with 10-100% ethyl acetate in heptane to obtain the marked compound (355 mg, 84%) as yellowish-brown rubber.
number
[0402] Intermediate 21 Ethyl 2-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate hydrochloride Intermediate 20 (165 mg, 0.282 mmol) was dissolved in ethanol (7 mL) and 1 M aqueous HCl (1.4 mL, 1.41 mmol). The reaction mixture was circulated three times between vacuum and nitrogen, and then 10% Pd / C (50% wet, 120 mg, 0.0564 mmol) was added. The reaction mixture was stirred at rt for 3 hours under a hydrogen atmosphere, and then filtered through a Celite® pad. The solid was washed with EtOH (50 mL) and siRNA (50 mL). The combined filtrate was concentrated to dryness and azeotropically mixed with toluene (3 × 3 mL) under vacuum to obtain the marked compound (16 mg, 100%) as a yellowish-brown solid.
number
[0403] Intermediate 22 Ethyl 1-(3,6-dichloropyridazine-4-yl)-4,4-difluorocyclohexanecarboxylate n-butyllithium (2.5 M, 7.2 mL, 18.0 mmol) in hexane was added dropwise to a stirred solution of dicyclohexylamine (3.6 mL, 18.1 mmol) in anhydrous toluene (24 mL) under nitrogen at 0°C. The resulting white suspension was stirred at 0°C for 20 minutes, then at 20°C for 30 minutes, and then cooled to 0°C. Ethyl 4,4-difluorocyclohexane-carboxylate (2.19 mL, 12.53 mmol) was added dropwise. The resulting yellow-orange turbid suspension was stirred at 0°C for 15 minutes, then at 20°C for 15 minutes, and then added under nitrogen to a dry flask containing 4-bromo-3,6-dichloropyridazine (95%, 2.50 g, 10.4 mmol) and methanesulfonate (tri-t-butylphosphin)(2'-methylamino-1,1'-biphenyl-2-yl)-palladium(II) [P(t-Bu)3 paradacycle fourth generation] (CAS number 1621274-11-0) (620 mg, 1.06 mmol). The mixture was stirred under nitrogen at 20°C for 18 hours, then diluted with DCM (50 mL) and quenched with 0.5 M hydrochloric acid aqueous solution (50 mL). The suspension was filtered through a Celite® pad and washed with DCM (50 mL) and water (30 mL). The organic phase was separated, and the aqueous layer was extracted with DCM (2 × 100 mL). The combined organic extract was washed with 0.5 M hydrochloric acid aqueous solution (50 mL) and brine (50 mL), then dried over magnesium sulfate and concentrated under vacuum. The residue was purified by silica column chromatography eluting with a gradient of 0 to 30% Â in heptane to obtain the marked compound (purity 76%) (859 mg, 19%) as an orange waxy solid.
number
[0404] Intermediate 23 Ethyl 1-[6-(tert-butoxycarbonylamino)-3-chloropyridazine-4-yl]-4,4-difluorocyclohexanecarboxylate Intermediate 22 (79%, 900 mg, 2.10 mmol), tert-butylcarbamate (296.5 mg, 2.53 mmol), and cesium carbonate (972 mg, 1.59 mmol) were suspended in anhydrous 1,4-dioxane (10.6 mL) and purged with nitrogen while sonicating for 5 minutes. Tris-(dibenzylideneacetone)dipalladium(0) (77.4 mg, 84.5 μmol) and Xantphos (97.2 mg, 0.17 mmol) were added. The mixture was purged with nitrogen while sonicating for 5 minutes, then sealed under nitrogen and heated at 90°C for 18 hours, and diluted with siRNA (20 mL). The solid was removed by filtration with Celite® and washing with siRNA (3 × 30 mL). The filtrate was concentrated under vacuum. The residue was purified by silica column chromatography using a gradient of elution in heptane from 0 to 40% Â to obtain the marked compound (purity 91%) (597 mg, 62%) as a yellowish-brown powder.
number
[0405] Intermediate 24 Ethyl 1-(6-amino-3-chloropyridazine-4-yl)-4,4-difluorocyclohexanecarboxylate TFA (2 mL, 26.9 mmol) was added to a stirred solution of intermediate 23 (91%, 615 mg, 1.33 mmol) in DCM (14 mL). The reaction mixture was stirred at 20°C for 4 hours, then quenched with saturated sodium bicarbonate aqueous solution (30 mL), and diluted with DCM (30 mL). The two-phase mixture was stirred at 20°C for 5 minutes, then the organic phase was separated and washed with saturated sodium bicarbonate aqueous solution (20 mL). The combined aqueous washing solution was extracted with DCM (2 × 30 mL). The combined organic extract was washed with brine (30 mL), dried over magnesium sulfate, and then concentrated under vacuum to obtain the marked compound (90% purity) (474 mg, 100%) as an orange-yellow powder.
number
[0406] Intermediate 25 Ethyl 1-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]-6-chloroimidazo[1,2-b]pyridazin-7-yl}-4,4-difluorocyclohexanecarboxylate A suspension of intermediate 24 (90%, 474 mg, 1.33 mmol), benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (639 mg, 1.58 mmol), and sodium bicarbonate (247 mg, 2.94 mmol) in IPA (7.3 mL) was sealed under nitrogen and heated at 65 °C for 18 hours. After cooling, the mixture was diluted with water (30 mL) and saturated sodium bicarbonate aqueous solution (10 mL), and then extracted with RINKAN (3 × 30 mL). The combined organic extract was washed with brine (30 mL), dried over magnesium sulfate, and concentrated under vacuum. The residue was purified by silica column chromatography eluting with a gradient of 5–60% RINKAN in heptane to obtain the marked compound (90% purity) (788 mg, 85%) as an orange viscous oil.
number
[0407] Intermediate 26 Ethyl 1-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorocyclohexanecarboxylate hydrochloride A suspension of intermediate 25 (90%, 788 mg, 1.13 mmol) and 10% palladium carbon (50% water-wet, 188 mg, 0.09 mmol) in 4:1 EtOH / water (17.5 mL) was placed under a hydrogen atmosphere and stirred at 20°C for 18 hours. The reaction mixture was filtered with Celite®, washed with EtOH (5 × 50 mL), and then concentrated under vacuum to obtain the marked compound (95% purity) (536 mg, 91%) as a yellowish-brown powder.
number
[0408] Intermediate 27 Ethyl 1-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]-methyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorocyclohexanecarboxylate HATU (400 mg, 1.05 mmol) was added to a stirred solution of intermediate 26 (95%, 400 mg, 0.77 mmol), 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (124 mg, 0.97 mmol), and DIPEA (0.35 mL, 2.00 mmol) in anhydrous DMF (4 mL). The reaction mixture was stirred under nitrogen at 20°C for 18 hours, then quenched with saturated sodium bicarbonate aqueous solution (10 mL), and diluted with water (10 mL). The substance was extracted with ELISA (3 × 30 mL). The combined organic extract was successively washed with 0.5 M hydrochloric acid / brine aqueous solution (1:1, 20 mL) and water / brine (1:1, 3 × 20 mL). The organic phase was dried over magnesium sulfate, then filtered, and concentrated under vacuum. The residue was purified by silica column chromatography using a gradient of elution in heptane from 0 to 60% Â to obtain the marked compound (purity 93%) (321 mg, 68%) as an off-white powder.
number
[0409] Intermediate 28 1-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]-methyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorocyclohexanecarboxylic acid A lithium hydroxide aqueous solution (1 M, 2.8 mL, 2.8 mmol) was added to a stirred solution of intermediate 27 (93%, 320 mg, 0.53 mmol) in MeOH (11 mL). The mixture was heated at 50°C for 24 hours. After cooling, volatile substances were removed under vacuum, and the aqueous residue was diluted with water (30 mL). The pH was adjusted to 1 with a 1 M hydrochloric acid aqueous solution, and the substance was extracted with ELISA (3 × 30 mL). The combined organic extract was washed with brine (30 mL), dried over magnesium sulfate, filtered, and concentrated under vacuum to obtain the labeled compound (92% purity) (330 mg, quantitative) as an off-white powder.
number
[0410] Intermediate 29 Methyl 2-[6-(tert-butoxycarbonylamino)pyridazin-4-yl]-4,4-difluorobutanoate Under N2 conditions, 10% palladium-carbon (220 mg, 0.207 mmol) was added to a solution of intermediate 4 (2.20 g, 6.05 mmol) in ethanol (60 mL). The reaction flask was placed under an H2 atmosphere, and the reaction mixture was stirred with rt for 20 hours. The mixture was then filtered through a Celite® pad and concentrated under vacuum. The crude product was purified by flash column chromatography eluting with a gradient of 0-50% siRNA in isohexane to obtain the marked compound (278 mg, 14%) as a colorless amorphous solid.
number
[0411] Intermediate 30 Methyl 2-(6-aminopyridazine-4-yl)-4,4-difluorobutanoate To a solution of intermediate 29 (345 mg, 1.04 mmol) in DCM (4.2 mL), TFA (4.2 mL) was added. The reaction mixture was heated at 40°C for 30 minutes and then concentrated under vacuum. The residue was dissolved in DCM (20 mL) and saturated sodium bicarbonate aqueous solution (20 mL). The aqueous layer was extracted with DCM (2 × 20 mL). The combined organic extracts were passed through a phase separator and then concentrated under vacuum to obtain the marked compound (157 mg, 65%) as an off-white amorphous solid.
number
[0412] Intermediate 31 Methyl 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate Sodium bicarbonate (82 mg, 0.98 mmol) was added to a solution of intermediate 30 (150 mg, 0.649 mmol) and benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (315 mg, 0.779 mmol) in IPA (3.2 mL). The reaction mixture was stirred overnight at 80°C and then concentrated under vacuum. The residue was dissolved in RINKAN (20 mL). The organic layer was washed with water (20 mL), and the aqueous layer was extracted with RINKAN (2 × 20 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography with elution in isohexane at a gradient of 0 to 80% RINKAN to obtain the marked compound (151 mg, 43%) as an off-white amorphous solid.
number
[0413] Intermediate 32 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]-pyridazin-7-yl}-4,4-difluorobutanoic acid To a solution of intermediate 31 (151 mg, 0.281 mmol) in THF (1.2 mL) and water (0.3 mL), lithium hydroxide monohydrate (24 mg, 0.56 mmol) was added. The reaction mixture was stirred at 40°C for 1 hour, then neutralized with 2 M hydrochloric acid aqueous solution (0.28 mL), and concentrated under vacuum to obtain the marked compound (146 mg, 99%) as a yellow amorphous solid.
number
[0414] Intermediate 33 Benzyl N-{(S)-(4,4-difluorocyclohexyl)[7-(3,3-difluoro-1-{[(1S)-2,2,2-trifluoro-1-methylethyl]carbamoyl}propyl)imidazo[1,2-b]pyridazin-2-yl]methyl}carbamate Intermediate 32 (146 mg, 0.279 mmol), (S)-2-amino-1,1,1-trifluoropropane hydrochloride (53 mg, 0.34 mmol), and DIPEA (0.15 mL, 0.84 mmol) were dissolved in DMF (2.8 mL) to which HATU (131 mg, 0.335 mmol) was added. The reaction mixture was stirred in rt for 10 minutes and then concentrated under vacuum. The residue was dissolved in DCM (20 mL) and washed with water (20 mL). The aqueous layer was extracted with DCM (2 × 20 mL), and the combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography eluting with a gradient of 0 to 60% siRNA in isohexane to obtain the marked compound (176 mg, 98%) as an off-white amorphous solid.
number
[0415] Intermediate 34 2-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]butanamide Under N2 conditions, 10% palladium-carbon (88 mg, 0.08 mmol) was added to a solution of intermediate 33 (176 mg, 0.274 mmol) in ethanol (2.7 mL). The reaction flask was placed under an H2 atmosphere, and the reaction mixture was stirred with rt for 3 hours. The mixture was then filtered through a Celite® pad and concentrated under vacuum to obtain the marked compound (109 mg, 82%) as a green oil.
number
[0416] Intermediate 35 5-(dicyclopropylmethyl)imidazolidined-2,4-dione Diammonium carbonate (47.10 g, 0.501 mol), 2,2-dicyclopropylacetaldehyde (95%, 26.10 g, 0.200 mol), and potassium cyanide (13.09 g, 0.201 mol) were stirred in a mixture of ethanol (140 mL) and water (140 mL) and heated at 60°C for 18 hours. To the cooled reaction mixture, 2N HCl (200 mL) and then 6N HCl (100 mL) were added little by little. A further 2N HCl (60 mL) was added, and the mixture was stirred at rt for 1 hour. A further 2N HCl (50 mL) was added to the mixture, the solid was filtered off, washed with water (2 × 200 mL), and dried to obtain the marked compound (purity 95%) (32.81 g, 80%) as a white solid.
number
[0417] Intermediate 36 2-(Benzyloxycarbonylamino)-3,3-dicyclopropylpropanoic acid To a stirred solution of intermediate 35 (95%, 1.00 g, 4.89 mmol) in 1,4-dioxane (6 mL), 5 M sodium hydroxide aqueous solution (6.0 mL, 30.0 mmol) was added. The mixture was heated at 100 °C for 18 hours, then 1,4-dioxane (6 mL) and water (6 mL) were added, and the mixture was heated at 120 °C for 2 days. To the cooled reaction mixture, TBME (10 mL) and water (10 mL) were added. The two-phase mixture was filtered. 6N HCl (6 mL) and TBME (10 mL) were added to the filtrate. Undissolved solids were filtered off. TBME (10 mL) was added to the filtrate. The layers were separated, and the aqueous layer was washed with TBME (3 × 10 mL). 5N NaOH aqueous solution (0.5 mL) was added to the aqueous layer, and the pH of the solution was adjusted to pH 7 using 6N HCl / 5N NaOH aqueous solution. To an aqueous solution (approximately 40 mL), THF (20 mL), then NaHCO3 (1.01 g), then disodium carbonate (1.01 g, 9.53 mmol), and then 1-(benzyloxycarbonyloxy)pyrrolidine-2,5-dione (0.90 g, 3.61 mmol) were added at rt. The mixture was stirred at rt for 2.5 days, then TBME (20 mL), followed by water (30 mL). The organic layer was separated. Water (10 mL) was added to the aqueous layer. The aqueous layer was washed with TBME (10 mL), then filtered, and washed again with TBME (10 mL). The pH of the aqueous layer was adjusted to pH 3 using 6N HCl (approximately 4 mL). Crystals from the previous batch were seeded, and then the flask was cooled externally and left for 2 hours. The contents were filtered, then washed with water (2 × 10 mL), and dried to obtain the labeled compound (719 mg, 49%) as a white solid.
number
[0418] Intermediate 37 tert-butyl 4-(benzyloxycarbonylamino)-5,5-dicyclopropyl-3-oxopentanoate Intermediate 36 (1.00 g, 3.30 mmol) was dissolved in anhydrous THF (12 mL) under nitrogen, and DIPEA (650 μL, 3.72 mmol), followed by HATU (1.40 g, 3.68 mmol), was added. The mixture was stirred under nitrogen for 1.5 hours. In a separate flask, a solution of LDA in THF / heptane / ethylbenzene (2 M, 7.0 mL, 14.0 mmol) and anhydrous THF (10 mL) was placed under nitrogen and cooled to -78°C. Tert-butyl acetate (1.9 mL, 14.2 mmol) was added dropwise over approximately 5 minutes. The resulting solution was stirred under nitrogen at -78°C for 1 hour, and then a separate solution of the activating acid was added dropwise while maintaining the internal temperature below -60°C. The resulting mixture was stirred under nitrogen at -78°C for 1 hour, and then quenched at -78°C by adding saturated aqueous NH4Cl (50 mL). The mixture was heated in rt and then extracted with ÃO (100 mL). The organic layer was washed with brine (50 mL), then dried with (Na2SO4), and concentrated to dryness under vacuum. The residue was purified by flash column chromatography eluting with 0-20% ÃO in heptane to obtain the marked compound (purity 85%) (1.15 g, 74%) as a pale yellow oil.
number
[0419] Intermediate 38 Benzyl N-[3-bromo-1-(dicyclopropylmethyl)-2-oxopropyl]carbamate Intermediate 37 (85%, 1.15 g, 2.43 mmol) was dissolved in methanol (5 mL), and 2,6-dimethylpyridine (30 μL, 0.258 mmol), followed by NBS (440 mg, 2.47 mmol), was added. The reaction mixture was stirred under nitrogen for 18 hours, diluted with toluene (50 mL), washed with a 50% mixture of water and brine (2 × 40 mL), washed with brine (20 mL), then dried, (Na₂SO₄), and concentrated to dryness under vacuum. The residue was dissolved in toluene (11 mL), and TFA (1.4 mL, 18.8 mmol) was added. The reaction mixture was stirred under nitrogen at 80°C for 2.5 hours, then cooled to rt, and concentrated to dryness under vacuum. The residue was purified by flash column chromatography using elution with 30-100% DCM in heptane, followed by 0-100% siRNA in DCM, to obtain the marked compound (purity 87%) (780 mg, 73%) as a colorless solid.
number
[0420] Intermediate 39 Ethyl 2-{2-[1-(benzyloxycarbonylamino)-2,2-dicyclopropylethyl]-6-chloroimidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate Intermediate 19 (365 mg, 1.305 mmol) and intermediate 38 (90%, 606.6 mg, 1.435 mmol) were dissolved in dry THF (10 mL), and sodium bicarbonate (328.9 mg, 3.915 mmol) was added. The reaction mixture was heated at 70°C for 18 hours with stirring, and then cooled to rt. The resulting solid was filtered and washed with DCM. The filtrate was concentrated under vacuum. The substance was purified by silica column chromatography eluting with a gradient of 0-40% ethyl acetate in heptane to obtain the marked compound (566 mg, 77%) as yellow / orange foam.
number
[0421] Intermediate 40 Ethyl 2-{2-[(1S)-1-amino-2,2-dicyclopropylethyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate hydrochloride Intermediate 39 (275 mg, 0.490 mmol) was dissolved in EtOH (15 mL), and 1 M aqueous HCl (2.45 mL, 2.450 mmol) was added, followed by 10% Pd / C (50% wet) (5.0%, 52.16 mg, 0.0245 mmol). The reaction mixture was stirred under 1 atm of H2 for 3 hours, then filtered through Celite®, concentrated under vacuum, and the solvent was removed. The residue was azeotropically mixed with toluene (3 × 3 mL) under vacuum to obtain the marked compound (190 mg, 90%) as a yellow solid.
number
[0422] Intermediate 41 Ethyl 2-(2-{(1S)-2,2-dicyclopropyl-1-[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]-ethyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorobutanoate Intermediate 40 (190 mg, 0.443 mmol) and 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (68 mg, 0.531 mmol) were stirred in anhydrous DMF (3 mL). DIPEA (232 μL, 1.329 mmol) was added, followed by HATU (202 mg, 0.531 mmol). The mixture was stirred at rt for 3 hours, then diluted with siRNA (30 mL) and washed with water (3 × 20 mL). The organic phase was dried over sodium sulfate, then filtered and concentrated to dryness under vacuum. The crude residue was purified by flash column chromatography eluting with a gradient of 0-40% ethyl acetate in heptane to obtain the marked compound (156 mg, 71%) as a yellow solid.
number
[0423] Intermediate 42 2-(2-{(1S)-2,2-dicyclopropyl-1-[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]ethyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluorobutanoic acid A mixture of lithium hydroxide monohydrate (29 mg, 0.679 mmol) and intermediate 41 (155 mg, 0.308 mmol) in THF (4 mL), water (0.6 mL), and methanol (1.5 mL) was stirred at rt for 16 hours. The reaction mixture was concentrated to a low volume under vacuum and then diluted with ethyl acetate (50 mL). HCl aqueous solution (0.5 M) was added until the pH reached 3. The layers were separated, and the aqueous layer was extracted with toluene (2 × 30 mL). The organic phase was washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness under vacuum to obtain the marked compound (142 mg, 97%) as a yellow solid.
number
[0424] Intermediate 43 Lithium 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-4,4-difluorobutanoate A mixture of lithium hydroxide monohydrate (56 mg, 1.29 mmol) and intermediate 58 (324 mg, 0.589 mmol) in THF (7 mL), water (1.5 mL), and methanol (3 mL) was stirred at rt for 2 hours. The reaction mixture was concentrated to dryness under vacuum, redissolved in toluene (5 mL), and concentrated again under vacuum. The residue was redissolved in toluene (5 mL), further concentrated twice under vacuum, and dried to obtain the marked compound (311 mg, 95%) as a yellow solid.
number
[0425] Intermediate 44 Benzyl N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethyl-carbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]carbamate HATU (671 mg, 1.77 mmol) was added at rt to a mixture of intermediate 43 (311 mg, 0.589 mmol) and DIPEA (308 μL, 1.77 mmol) in anhydrous DMF (8 mL). The reaction mixture was stirred at rt for 5 minutes, and then 2,2,2-trifluoroethaneamine (139 μL, 1.77 mmol) was added. The reaction mixture was stirred at rt for 16 hours, then diluted with HCl (50 mL) and washed with water (3 × 60 mL). The organic phase was dried over sodium sulfate, then filtered and concentrated to dryness. The resulting crude material was purified by FCC (Biotage Isolera, SiO2, gradient elution 10-60% HCl:heptane) to obtain the marked compound (246 mg, 68%) as yellow rubber.
number
[0426] Intermediate 45 Benzyl N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethyl-carbamoteoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]carbamate Lawson's reagent (85 mg, 0.210 mmol) was added under nitrogen to a solution of intermediate 44 (211 mg, 0.350 mmol) in anhydrous 1,4-dioxane (2 mL). The reaction mixture was stirred at 90°C for 22 hours, then diluted with ethyl acetate (60 mL) and washed with saturated NaHCO3 aqueous solution (20 mL). The aqueous layer was extracted with ethyl acetate (2 × 30 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness under vacuum. The resulting crude material was purified by FCC (Biotage Isolera, gradient elution 10-60% ethyl acetate: heptane) to obtain the labeled compound (154 mg, 71%) as yellowish-brown rubber.
number
[0427] Intermediate 46 Benzyl N-[(S)-(4,4-difluorocyclohexyl)(7-{3,3-difluoro-1-[1-(2,2,2-trifluoroethyl)-tetrazole-5-yl]propyl}imidazo[1,2-b]pyridazin-2-yl)methyl]carbamate Triphenylphosphine (98 mg, 0.373 mmol) was added at rt to a solution of intermediate 45 (154 mg, 0.249 mmol), DIAD (73 μL, 0.373 mmol), and azide(trimethyl)silane (98 μL, 0.746 mmol) in anhydrous THF (0.8 mL). The reaction mixture was stirred at rt for 3 days, then diluted with HCl (40 mL) and washed with saturated NaHCO3 aqueous solution. The aqueous phase was re-extracted with HCl (3 × 30 mL). The organic phase was dried over sodium sulfate, then filtered and concentrated to dryness under vacuum. The resulting crude material was purified by FCC (Biotage Isolera, SiO2, gradient elution 10-50% HCl:heptane) to obtain the marked compound (122 mg, 62%) as yellowish-brown rubber.
number
[0428] Intermediate 47 (S)-(4,4-difluorocyclohexyl)(7-{3,3-difluoro-1-[1-(2,2,2-trifluoroethyl)tetrazole-5-yl]-propyl}imidazo[1,2-b]pyridazin-2-yl)methanamine Intermediate 46 (122 mg, 0.194 mmol) was dissolved in EtOH (14 mL) and water (1.4 mL). The reaction mixture was circulated three times between vacuum and nitrogen, and then palladium carbon (10% packed, 50% water) (5.0%, 83 mg, 0.0388 mmol) was added. The reaction mixture was circulated three times between vacuum and hydrogen, and then stirred at rt under a hydrogen atmosphere for 22 hours. Hydrogen was purged from the reaction vessel by circulating it three times between vacuum and nitrogen. The reaction mixture was filtered through a Celite® pad, and the solid was washed with EtOH (3 × 30 mL). The combined filtrate was concentrated to dryness, and then azeotropically reacted with toluene (3 × 3 mL) under vacuum to obtain the marked compound (96 mg, 100%) as a pale yellowish-brown rubber.
number
[0429] Intermediate 48 Benzyl N-[(S)-(7-chloroimidazo[1,2-b]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl]carbamate A solution of benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]-carbamate (1.65 g, 4.08 mmol), 5-chloropyridazine-3-aminetrifluoroacetate (900 mg, 3.670 mmol), and sodium bicarbonate (650 mg, 7.74 mmol) in 2-propanol (40 mL) was stirred at 80°C for 18 hours. The reaction mixture was concentrated under vacuum. The residue was purified by flash column chromatography eluting with a gradient of 0-35% siRNA in isohexane, and then lyophilized in water / acetonitrile to obtain the marked compound (758 mg, 47%) as a pale powder.
number
[0430] Intermediate 49 O 1 -tert-butylO 3-Ethyl 4-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)-methyl]imidazo[1,2-b]pyridazin-7-yl}2,5-dihydropyrrole-1,3-dicarboxylate Bis(pinacolato)diborone (370 mg, 1.46 mmol), potassium acetate (325 mg, 3.28 mmol), tris(dibenzylidene actaeon)dipalladium (0) (120 mg, 0.13 mmol), XPhos (130 mg, 0.26 mmol), and O 1 -tert-butylO 3 Ethyl 4-(trifluoromethylsulfonyloxy)-2,5-dihydropyrrole-1,3-dicarboxylate (International Publication No. 2020 / 261141, Intermediate 4) (513 mg, 1.3 mmol) was placed in a vial, followed by the addition of anhydrous 1,4-dioxane (2.6 mL). The reaction mixture was completely degassed and then heated at 100°C for 2 hours. Intermediate 48 (460 mg, 1.06 mmol) was added, followed by the addition of tribasic potassium phosphate (425 mg, 2.00 mmol) in water (1.1 mL). The mixture was again degassed and heated at 90°C for 1 hour, then diluted with ELISA (50 mL) and washed with water (2 × 50 mL). The aqueous layer was re-extracted with ELISA (50 mL). The combined organic extracts were passed through a hydrophobic frit and concentrated under vacuum. The residue was purified by flash column chromatography using a elution gradient of 0–100% siRNA in isohexane, and then lyophilized in water / acetonitrile to obtain the marked compound (486 mg, 72%) as a pale yellow solid.
number
[0431] Intermediate 50 Lithium 4-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-1-(tert-butoxycarbonyl)-2,5-dihydropyrrole-3-carboxylate To a stirred solution of intermediate 49 in EtOH (9 mL), lithium hydroxide monohydrate (67 mg, 1.60 mmol) was added in water (3 mL). After 5 hours, the reaction mixture was concentrated under vacuum and then freeze-dried in water / acetonitrile to obtain the labeled compound (489 mg, quantitatively determined) as a yellow solid.
number
[0432] Intermediate 51 tert-butyl3-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo-[1,2-b]pyridazin-7-yl}-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)-2,5-dihydropyrrole-1-carboxylate To a solution of intermediate 50 (473 mg, 0.77 mmol) in DMF (2.60 mL) and DIPEA (0.53 mL, 3.0 mmol), 3,3,4,4-tetrafluoropyrrolidine hydrochloride (167 mg, 0.93 mmol), followed by HATU (328 mg, 0.85 mmol), was added. The mixture was stirred for 2 hours and then diluted with saturated sodium bicarbonate aqueous solution (30 mL) and DCM (30 mL). The organic layer was separated, and the aqueous layer was re-extracted with DCM (3 × 30 mL). The combined organic layers were dried and concentrated. The residue was purified by flash column chromatography eluting with a gradient of 0 to 100% siRNA in isohexane, and then lyophilized in water / acetonitrile to obtain the marked compound (475 mg, 84%) as a pale yellow solid.
number
[0433] Intermediate 52 tert-butyl(3RS,4RS)-3-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]-pyridazin-7-yl}-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate To a stirred solution of intermediate 51 (280 mg, 0.38 mmol) in EtOH (4 mL), palladium carbon hydroxide (30 mg, 0.043 mmol) and ammonium formate (481 mg, 7.63 mmol) were added. The reaction mixture was completely degassed and then left under a hydrogen atmosphere for 18 hours. An additional 26 mg of palladium carbon hydroxide was added. The reaction mixture was degassed and left under a hydrogen atmosphere for 36 hours, then filtered through Celite® and concentrated under vacuum. The residue was dissolved in DCM (10 mL) and washed with 1.5 M aqueous sodium carbonate solution (10 mL). The aqueous layer was re-extracted with DCM (10 mL). The combined organic extracts were passed through a phase separator and then concentrated under vacuum to obtain the marked compound (a mixture of pyrrolidinecis isomers) (230 mg, quantitatively) as black foam.
number
[0434] Intermediate 53 tert-butyl(3RS,4RS)-3-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]methyl}imidazo[1,2-b]pyridazin-7-yl)-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate) To a solution of intermediate 52 (230 mg, 0.38 mmol) in DMF (3.2 mL) and DIPEA (0.20 mL, 1.1 mmol), 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (65 mg, 0.48 mmol), followed by HATU (189 mg, 0.48 mmol), was added. The reaction mixture was stirred for 1.5 hours, then diluted with water (25 mL) and extracted with RINKAN (3 × 25 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The residue was purified by flash column chromatography eluting with a gradient of 0–100% RINKAN in isohexane, and then lyophilized in water / acetonitrile to obtain the marked compound (a mixture of pyrrolidinecis isomers) (171 mg, 44%) as an off-white solid.
number
[0435] Intermediate 54 N-[(S)-(4,4-difluorocyclohexyl){7-[(3RS,4RS)-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidine-3-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide To a solution of intermediate 53 (75 mg, 0.10 mmol) in DCM (2 mL), 4 M HCl in 1,4-dioxane (2 mL) was added. The reaction mixture was stirred for 1.5 hours and then concentrated under vacuum. The residue was partitioned into RINKAN (20 mL) and saturated sodium bicarbonate aqueous solution (20 mL). The layers were separated, and the aqueous layer was re-extracted with RINKAN (2 × 20 mL). The combined organic extracts were dried, concentrated under vacuum, and then freeze-dried in water / acetonitrile to obtain the marked compound (a mixture of pyrrolidinecis isomers) (63.3 mg, 98%) as an off-white solid.
number
[0436] Intermediate 55 tert-butyl 2-(6-aminopyridazine-4-yl)-4,4-difluoropiperidine-1-carboxylate Solutions of 5-chloropyridazine-3-amine (300 mg, 2.31 mmol), 1-(tert-butoxycarbonyl)-4,4-difluoropiperidine-2-carboxylic acid (920 mg, 3.47 mmol), {Ir[dF(CF3)ppy]2(dtbpy)}PF6 (50.0 mg, 44.6 μmol), nickel(II) chloride ethylene glycol dimethyl ether complex (50.0 mg, 0.228 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (93.0 mg, 0.346 mmol), and cesium carbonate (1.13 g, 3.47 mmol) in DMF (25 mL) were purged with nitrogen gas for 5 minutes and then irradiated under a 450 nm LED for 72 hours. The solvent was removed under reduced pressure. The residue was purified by silica column chromatography using elution with 0-20% MeOH in RINKAN to obtain the crude labeled compound (440 mg, 60%) as an orange solid, which was used without further purification.
number
[0437] Intermediate 56 tert-butyl2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo-[1,2-b]pyridazin-7-yl}-4,4-difluoropiperidine-1-carboxylate The intermediate 55 (430 mg, 1.37 mmol), benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (660 mg, 1.63 mmol), and sodium bicarbonate (140 mg, 1.66 mmol) were mixed in 2-propanol (15 mL) and stirred overnight at 80°C. The reaction mixture was concentrated, and the residue was purified by silica column chromatography eluting with 0-40% ethylethanol in hexane to obtain the marked compound (86 mg, 7%) as an orange solid.
number
[0438] Intermediate 57 tert-butyl2-(2-{(S)-(4,4-difluorocyclohexyl)[(4-methyl-1,2,5-oxadiazole-3-carbonyl)-amino]methyl}imidazo[1,2-b]pyridazin-7-yl)-4,4-difluoropiperidine-1-carboxylate A mixture of intermediate 56 (87.0 mg, 98 μmol), hydrogen chloride in 1,4-dioxane (4.0 M, 70.0 μL, 0.28 mmol), and palladium carbon (10 wt / wt% packed, 20.0 mg) in ethanol (5 mL) was stirred at rt for 5 hours under a hydrogen atmosphere. The reaction mixture was filtered and washed with ethanol (5 mL). The filtrate was concentrated. The residue was combined with HATU (47.0 mg, 0.12 mmol), 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (16.0 mg, 0.12 mmol), and DIPEA (0.10 mL, 0.60 mmol) and suspended in DMF (1.0 mL). The mixture was stirred at rt for 2 hours, and then the solvent was removed under reduced pressure. The residue was purified by silica column chromatography using elution with 0-40% siRNA in hexane to obtain the labeled compound (46 mg, 78%) as a yellow oil.
number
[0439] Intermediate 58 Ethyl 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]-pyridazin-7-yl}-4,4-difluorobutanoate N-(benzyloxycarbonyloxy)succinimide (1.90 g, 7.41 mmol) was added to a solution of intermediate 21 (2.80 g, 6.17 mmol) and triethylamine (2.58 mL, 18.5 mmol) in DCM (62 mL). The reaction mixture was stirred in rt for 10 minutes, then diluted with DCM (40 mL) and washed with water (100 mL). The aqueous layer was diluted with DCM (2 × 50 mL), and the combined organic extract was washed with brine (100 mL). The organic layer was passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography eluting with a gradient of 0 to 60% siRNA in isohexane to obtain the marked compound (3.13 g, 92%) as an off-white amorphous solid.
number
[0440] Intermediate 59 2-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]-pyridazin-7-yl}-4,4-difluorobutanoic acid To a solution of intermediate 58 (1.20 g, 2.18 mmol) in THF (8.8 mL) and water (2.2 mL), lithium hydroxide monohydrate (186 mg, 4.36 mmol) was added. The reaction mixture was heated to 40 °C and stirred for 3.5 hours. Then, it was neutralized with aqueous HCl (2 M, 2.2 mL) and concentrated under vacuum to obtain the marked compound (1.32 g, 116%) as a yellow amorphous solid.
number
[0441] Intermediate 60 Benzyl N-{(S)-(4,4-difluorocyclohexyl)[7-(3,3-difluoro-1-{[(5-fluoropyridine-2-yl)-amino]carbamoyl}propyl)imidazo[1,2-b]pyridazin-2-yl]methyl}carbamate To a solution of intermediate 59 (1.14 g, 2.18 mmol) in toluene (21.8 mL), pyridine (0.88 mL, 10.9 mmol), followed by T3P® solution (toluene, 1.68 mol / L in 3.24 mL, 5.45 mmol). The mixture was stirred for 5 minutes, then (5-fluoropyridine-2-yl)-hydrazine (339 mg, 2.62 mmol) was added. The reaction mixture was heated to 40°C, stirred for 5 minutes, and then cooled to rt. A small amount of ice was added, and the mixture was stirred for a further 5 minutes. toluene (50 mL) was added, and the organic layer was washed with water (50 mL). The aqueous layer was extracted with toluene (2 × 50 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude substance was purified by silica column chromatography using an elution gradient of 0-100% Â in isohexane to obtain the labeled compound (755 mg, 55%) as an orange amorphous solid.
number
[0442] Intermediate 61 Benzyl N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]-pyridine-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]carbamate To a solution of intermediate 60 (750 mg, 1.19 mmol) at 0°C in THF (3 mL), triethylamine (0.66 mL, 4.75 mmol), followed by triphenylphosphine (623 mg, 2.38 mmol) and hexachloroethane (568 mg, 2.38 mmol) were added. The reaction mixture was heated to 40°C and stirred for 1.5 hours. It was then diluted with ₹ (40 mL) and washed with water (40 mL). The aqueous layer was extracted with ₹ (2 × 20 mL). The combined organic layers were passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography eluting in isohexane with a gradient of 0–100% ₹ to obtain the marked compound (706 mg, 97%) as an off-white amorphous solid.
number
[0443] Intermediate 62 (S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methanamine To a solution of intermediate 61 (700 mg, 1.14 mmol) at 0°C in DCM (11.4 mL), boron tribromide solution (1.0 M in DCM) (2.28 mL, 2.28 mmol) was added dropwise. The reaction mixture was heated in rt and stirred for 1.5 hours, then quenched with saturated sodium bicarbonate aqueous solution (20 mL). The aqueous layer was extracted using DCM (3 × 20 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude substance was purified by silica column chromatography with elution at a gradient of 0-20% MeOH in DCM to obtain the marked compound (361 mg, 66%) as a colorless amorphous solid.
number
[0444] Intermediate 63 tert-butyl N-(5-chloropyridazine-3-yl)carbamate Palladium(II) acetate (4.60 g, 20.5 mmol) was added to a nitrogen-degassed mixture of 3,5-dichloropyridazine (60.00 g, 0.403 mol), tert-butylcarbamate (48.63 g, 0.415 mol), cesium carbonate (266 g, 0.819 mol), and Xantphos (23.51 g, 40.6 mmol) in dried 1,4-dioxane (0.6 L). The reaction mixture was further degassed and then heated at 80°C for 18 hours. The cooled reaction mixture was filtered through Celite® and rinsed with 1,4-dioxane (4 × 150 mL). The filtrate was concentrated under vacuum and then DCM (0.25 L), water (0.25 L), and brine (0.25 L) were added. The two-phase system was filtered through glass fiber paper, retaining the organic layer. The aqueous layer was re-extracted with DCM (100 mL). The organic layers were combined, dried over magnesium sulfate, filtered, and concentrated under vacuum. The residue was dissolved in DCM (100 mL) and purified by dry flash chromatography eluting with 0-30% siRNA in heptane to obtain the marked compound (37.8 g, 41%) as an off-white solid.
number
[0445] Intermediate 64 Methyl 4-[6-(tert-butoxycarbonylamino)pyridazine-4-yl]tetrahydropyran-4-carboxylate A solution of methyltetrahydropyran-4-carboxylate (0.51 mL, 3.8 mmol) and intermediate 63 (0.44 g, 1.92 mmol) in THF (10 mL) was added dropwise to lithium bis(trimethylsilyl)amide (1.0 M in toluene) (5.8 mL, 5.8 mmol) under nitrogen at 0°C. The reaction mixture was stirred at 0°C for 3 hours, then at rt for a further 2 hours, and then quenched by adding saturated NH4Cl aqueous solution (50 mL) and DCM (40 mL). The layers were separated, and the aqueous layer was extracted with DCM (2 × 20 mL). The combined organic layers were passed through a phase separator and concentrated under vacuum. The crude residue was purified by flash column chromatography with elution in hexane under a gradient of 0 to 100% siRNA to obtain the marked compound (350 mg, 54%) as a white solid.
number
[0446] Intermediate 65 Methyl 4-(6-aminopyridazine-4-yl)tetrahydropyran-4-carboxylate To a solution of intermediate 64 (341 mg, 1.01 mmol) in DCM (5 mL), TFA (2.5 mL) was added. The reaction mixture was stirred in rt for 1 hour, then concentrated under vacuum and diluted with DCM (20 mL). The organic layer was washed with saturated sodium bicarbonate aqueous solution (20 mL), and the aqueous layer was back-extracted with a mixture of MeOH in DCM (2%, 2 × 20 mL). The combined organic extracts were passed through a phase separator and then concentrated under vacuum to obtain the marked compound (250 mg) as a colorless amorphous solid, which was used without further purification.
number
[0447] Intermediate 66 Methyl 4-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}tetrahydropyran-4-carboxylate A mixture of intermediate 65 (240 mg, 1.01 mmol), benzyl N-[(1S)-3-bromo-1-(4,4-difluorocyclohexyl)-2-oxopropyl]carbamate (613 mg, 1.52 mmol), and sodium bicarbonate (170 mg, 2.02 mmol) was mixed with 2-propanol (5 mL). The reaction mixture was stirred overnight at 80°C and then concentrated under vacuum. The residue was dissolved in HCl (20 mL) and washed with water (20 mL). The aqueous layer was extracted with HCl (2 × 20 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude substance was purified by column chromatography (Biotage SFAR HC DUO, 25 g, Isolera) with elution in isohexane at a gradient of 0 to 80% HCl to obtain the marked compound (304 mg, 53%) as an orange solid.
number
[0448] Intermediate 67 Lithium 4-{2-[(S)-benzyloxycarbonylamino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}tetrahydropyran-4-carboxylate Intermediate 66 (300 mg, 0.53 mmol) was dissolved in THF (2 mL) and treated with lithium hydroxide monohydrate (53 mg, 1.24 mmol) dissolved in water (1 mL). MeOH (1 mL) was added to aid dissolution. The mixture was stirred overnight and then evaporated under vacuum to obtain the marked compound (304 mg, 92%) as a white solid, which was used without further purification.
number
[0449] Intermediate 68 Benzyl N-[(S)-(4,4-difluorocyclohexyl){7-[4-(2,2-difluoropropylcarbamoyl)-tetrahydropyran-4-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]carbamate Intermediate 67 (302 mg, 0.535 mmol) and 2,2-difluoropropylamine hydrochloride (82 mg, 0.59 mmol) were suspended in DCM (10 mL) and treated with DIPEA (3 mL, 17.2 mmol). The mixture was stirred for 1 minute, and then HATU (218 mg, 0.562 mmol) was added. DMF (1 mL) was added to aid dissolution. The mixture was stirred overnight, and then siRNA (50 mL) and brine (50 mL) were separated. The organic layer was washed with brine (3 × 20 mL), then passed through hydrophobic frit and evaporated under vacuum. The brown rubber was purified by silica column chromatography eluting with siRNA in DCM with a 0–100% gradient to obtain the labeled compound (250 mg, 73%).
number
[0450] Intermediate 69 4-{2-[(S)-amino(4,4-difluorocyclohexyl)methyl]imidazo[1,2-b]pyridazin-7-yl}-N-(2,2-difluoropropyl)tetrahydropyran-4-carboxamide Intermediate 68 (245 mg, 0.397 mmol) was dissolved in ethanol (10 mL) and degassed with nitrogen. Palladium carbon (50 mg, 0.047 mmol) was added. The reaction mixture was placed under a hydrogen gas atmosphere and stirred at rt for 24 hours. Then, it was filtered with Celite®, washed with DCM, and evaporated under vacuum to obtain the marked compound (200 mg, 97%) as a pale gray solid.
number
[0451] Example 1 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide To a solution of 2-chloro-1-methylpyridinium iodide (21 mg, 0.0809 mmol) in DMA (0.2 mL), DIPEA (0.055 mL, 0.311 mmol) and 2,2,2-trifluoroethanamine (0.0074 mL, 0.0933 mmol) were added. Intermediate 13 (31 mg, 0.0622 mmol) in DMA was added. The reaction mixture was heated at 50°C for 18 hours, then cooled and diluted with  (10 mL), water (10 mL), and brine (10 mL). The organic layer was dried over magnesium sulfate, and the solvent was removed under vacuum. The resulting brown oil was purified by silica column chromatography eluting with 0-50%  in heptane to obtain the marked compound (19 mg, 53%) as light brown rubber.
number
[0452] Example 2 [ka] N-{(S)-(4,4-difluorocyclohexyl)[7-(3,3-difluoro-1-{[(1R)-2-methyl-1-(methylcarbamoyl)-propyl]carbamoyl}propyl)imidazo[1,2-b]pyridazin-2-yl]methyl}-4-methyl-1,2,5-oxadiazole-3-carboxamide To a solution of intermediate 13 (40 mg, 0.0803 mmol) in DMF (1 mL), DIPEA (70 μL, 0.401 mmol), intermediate 15 (89 mg, 0.241 mmol), and HATU (37 mg, 0.0963 mmol) were added. The reaction mixture was stirred for 18 hours, then diluted with water (10 mL) and extracted with SiO2 (25 mL). The organic layer was washed with water (3 × 10 mL), dried over magnesium sulfate, and then the solvent was removed. The resulting oil was purified by silica column chromatography eluting with 0-70% SiO2 in heptane to obtain the marked compound (30 mg, 61%) as a white solid.
number
[0453] Examples 3A and 3B [ka] N-[(S)-{7-[(1R)-1-{[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]carbamoyl}-3,3-difluoropropyl]imidazo[1,2-b]pyridazin-2-yl}(4,4-difluorocyclohexyl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide N-[(S)-{7-[(1S)-1-{[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]carbamoyl}-3,3-difluoropropyl]imidazo[1,2-b]pyridazin-2-yl}(4,4-difluorocyclohexyl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide Intermediate 13 (94 mg, 0.188 mmol) in DMA (1 mL) was added to a solution of 2-chloro-1-methylpyridinium iodide (63 mg, 0.244 mmol), (1S)-1-cyclopropyl-2,2,2-trifluoroethaneamine (31 mg, 0.225 mmol), and DIPEA (164 μL, 0.939 mmol) in DMA (1 mL). The reaction mixture was heated in a sealed tube at 50°C for 1 hour, then diluted with water (10 mL), and extracted with ethyl acetate (2 × 10 mL). The organic extract was dried over sodium sulfate and concentrated under vacuum. The residue was purified by silica column chromatography eluting with a gradient of 0–100% ethyl acetate in heptane, then by reversed-phase column chromatography eluting with a 5–100% acetonitrile aqueous solution containing 0.1% formic acid, and then by preparative HPLC (Method 9). Stereoisomers were separated by chiral HPLC (Chiralcel OD-H, 20 × 250 mm, 5 μm, eluted with 95% heptane and 5% IPA at 18 mL / min) to obtain the marked compound (peak 1, 13 mg, 11%; and peak 2, 22 mg, 19%) as a white solid. Peak 1:
number
number
[0454] General method 1 Intermediate 11 (72 mg, 0.153 mmol) and a specific carboxylic acid derivative (0.169 mmol) were stirred in DMF (1 mL). DIPEA (0.055 mL, 0.307 mmol) was added, followed by HATU (70 mg, 0.184 mmol). The reaction mixture was stirred for 40 minutes and then diluted with ethyl acetate (3 mL). The resulting substance was washed with water (2 mL), saturated NH4Cl aqueous solution (2 mL), water (2 mL), and brine (2 mL), and then concentrated under vacuum. The residue was purified by reversed-phase column chromatography eluting with a gradient of 5-100% acetonitrile aqueous solution containing 0.1% formic acid, followed by preparative HPLC (Method 9).
[0455] Examples 4A and 4B [ka] 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(2,2,2-trifluoro-ethylcarbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(2,2,2-trifluoro-ethylcarbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide The compound was prepared from 4-cyclopropyl-1,2,5-oxadiazole-3-carboxylic acid (26 mg, 0.169 mmol) according to General Method 1, and the stereoisomers were subsequently separated by chiral SFC (Chiralcel OJ-H, 10 × 250 mm, 5 μm, eluted at 15 mL / min with 5% MeOH and 95% CO2) to obtain the marked compound (peak 1, 10 mg, 11%; and peak 2, 10 mg, 11%) as a white solid. Peak 1:
number
number
[0456] Example 5 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethyl-1,2,5-oxadiazole-3-carboxamide The marked compound (50 mg, 54%) was prepared from 4-ethyl-1,2,5-oxadiazole-3-carboxylic acid (24 mg, 0.169 mmol) according to General Method 1, and was obtained as a white solid.
number
[0457] Examples 6A and 6B [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethylisoxazole-3-carboxamide N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethylisoxazole-3-carboxamide The compound was prepared from 4-ethylisoxazole-3-carboxylic acid (24 mg, 0.169 mmol) according to General Method 1, and the stereoisomers were subsequently separated by chiral SFC (Chiralcel OJ-H, 10 × 250 mm, 5 μm, eluted at 15 mL / min with 5% IPA and 95% CO2) to obtain the marked compound (peak 1, 10 mg, 11%; and peak 2, 8 mg, 9%) as a white solid. Peak 1:
number
number
[0458] Example 7 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-2-isopropylpyrazole-3-carboxamide The marked compound (53 mg, 56%) was prepared from 1-isopropyl-1H-pyrazole-5-carboxylic acid (26 mg, 0.169 mmol) according to General Method 1, and was obtained as a white solid.
number
[0459] Example 8 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-2-isopropyl-1,2,4-triazole-3-carboxamide The marked compound (48 mg, 50%) was prepared from 2-isopropyl-1,2,4-triazole-3-carboxylic acid (26 mg, 0.169 mmol) according to General Method 1, and was obtained as a white solid.
number
[0460] Example 9 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[4,4-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-cyclohexyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide HATU (131 mg, 0.34 mmol) was added to a stirred solution of intermediate 28 (92%, 150 mg, 0.26 mmol), 2,2,2-trifluoroethaneamine (42 μL, 0.53 mmol), and DIPEA (92 μL, 0.53 mmol) in anhydrous DMF (2.6 mL). The reaction mixture was stirred under nitrogen at 20 °C for 18 hours, then quenched with saturated sodium bicarbonate aqueous solution (10 mL), and diluted with water (10 mL). The resulting substance was extracted with RINKAN (3 × 30 mL). The combined organic extracts were successively washed with 0.5 M hydrochloric acid / brine aqueous solution (1:1, 20 mL) and water / brine (1:1, 3 × 20 mL). The organic phase was dried over magnesium sulfate, then filtered, and concentrated under vacuum. The residue was purified by basic preparative HPLC to obtain the labeled compound (98% purity) (118 mg, 73%) as a white powder.
number
[0461] Examples 10A and 10B [ka] 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-{[(1S)-2,2,2-trifluoro-1-methylethyl]carbamoyl}propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-{[(1S)-2,2,2-trifluoro-1-methylethyl]carbamoyl}propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide Intermediate 34 (109 mg, 0.226 mmol), 4-cyclopropyl-1,2,5-oxadiazole-3-carboxylic acid (35 mg, 0.23 mmol), and DIPEA (88 mg, 0.68 mmol) were dissolved in DMF (2.3 mL) to which HATU (106 mg, 0.270 mmol) was added. The reaction mixture was stirred in rt for 5 minutes, then diluted with DCM (20 mL) and washed with water (20 mL). The aqueous layer was extracted with DCM (2 × 20 mL), and the combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography with elution in isohexane under a gradient of 0 to 80% siRNA. The resulting diastereomer mixture (1:1) was subjected to chiral SFC purification by elution with 3% MeOH (+0.1% NH4OH) in CO2 (Chiralpak IC 250×20mm, 5μm column, flow rate 100mL / min, 60 bar, column temperature 40°C), and after lyophilization, the indicated compound (peak 1, 20 mg, 20%; and peak 2, 23 mg, 23%) was obtained. Peak 1:
number
number
[0462] Example 11 [ka] N-(2,2-dicyclopropyl-1-{7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)propyl]-imidazo[1,2-b]pyridazin-2-yl}ethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide Intermediate 42 (140 mg, 0.295 mmol) in DMA (1 mL) was added to a solution of 2-chloro-1-methylpyridinium iodide (98 mg, 0.383 mmol), 2,2,2-trifluoroethaneamine (52.6 mg, 0.531 mmol), and DIPEA (154.6 μL, 0.885 mmol) in DMA (1 mL). The reaction mixture was heated in a sealed tube at 50°C for 2 hours, then diluted with water (10 mL) and extracted with ethyl acetate (2 × 15 mL). The organic extract was dried over sodium sulfate and concentrated under vacuum. The residue was purified by column chromatography eluting with a gradient of 0-50% ethyl acetate in heptane to obtain the marked compound (131 mg, 80%) as an off-white solid.
number
[0463] Example 12 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]-pyridine-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]-pyridine-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide HATU (49 mg, 0.13 mmol) was added to a solution of intermediate 62 (50 mg, 0.10 mmol), 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (17 mg, 0.13 mmol), and DIPEA (0.05 mL, 0.31 mmol) in DMF (0.52 mL). The reaction mixture was stirred in rt for 10 minutes and then diluted with DCM (5 mL) and water (5 mL). The aqueous layer was extracted with DCM (2 × 5 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The crude material was purified by silica column chromatography eluting with a gradient of 0 to 100% siRNA in isohexane, followed by preparative HPLC, to obtain a mixture of two stereoisomers. The desired stereoisomer was isolated by chiral HPLC (Chiralpak IC 250 × 20 mm, 5 μm, eluted with 3-40% MeOH (+0.1% NH4OH) at 100 mL / min) with the second elution peak at RT 7.29 min, yielding the marked compound (3.5 mg, 27%) as a colorless amorphous solid. The undesirable first elution peak has an RT of 6.91 min. The absolute stereochemistry of the carbon atom adjacent to the difluoroethyl group is unknown.
number
[0464] Example 13 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[1-(oxetan-3-yl)-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidine-3-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide To a solution of intermediate 54 (63 mg, 0.10 mmol) in DCM (3 mL), oxetane-3-one (7.3 μL, 0.11 mmol) and acetic acid (6.48 μL, 0.11 mmol) were added. The mixture was stirred for 5 minutes, and then sodium triacetoxyborohydride (35 mg, 0.16 mmol) was added. The mixture was stirred for 18 hours, and then a further portion of oxetane-3-one (7.3 μL, 0.11 mmol) and sodium triacetoxyborohydride (35 mg, 0.16 mmol) was added. The reaction mixture was stirred at rt for 5 hours, and then partitioned into DCM (20 mL) and brine (20 mL). The layers were separated, and the aqueous layer was re-extracted with DCM (2 × 20 mL). The combined organic extracts were passed through a phase separator and concentrated under vacuum. The residue was purified by flash column chromatography using a gradient of 0–40% MeOH in ethyl acetate. The resulting substance (a 1:1 mixture of pyrrolidine cis isomers) was subjected to chiral SFC purification (Chiralpak IC 250×20mm, 5μm column, flow rate 100mL / min, column temperature 40°C, elution by 3–40% MeOH (+0.1% NH4OH)), and the labeled compound (9 mg, 13%) was obtained as the first elution peak. The absolute stereochemistry of the pyrrolidine ring is unknown.
number
[0465] Example 14 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[4-(2,2-difluoropropylcarbamoyl)tetrahydropyran-4-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide Intermediate 69 (50 mg, 0.095 mmol), DIPEA (0.03 mL, 0.2 mmol), and 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (15 mg, 0.11 mmol) were dissolved in DCM (5 mL), and then HATU (50 mg, 0.13 mmol) was added. The reaction mixture was stirred overnight, then diluted with DCM (10 mL), washed with water (10 mL), passed through hydrophobic frit, and evaporated. The residue was dissolved in MeOH and then purified by preparative HPLC to obtain the marked compound (10 mg, 18%) as a white solid.
number
[0466] Example 15 [ka] N-[(S)-(4,4-difluorocyclohexyl)(7-{(1S*)-3,3-difluoro-1-[1-(2,2,2-trifluoroethyl)tetrazol-5-yl]propyl}imidazo[1,2-b]pyridazin-2-yl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide HATU (111 mg, 0.291 mmol) was added at rt to a mixture of 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (37 mg, 0.291 mmol) and DIPEA (0.081 mL, 0.466 mmol) in anhydrous DMF (3 mL). The reaction mixture was stirred at rt for 5 minutes, and then intermediate 47 (96 mg, 0.194 mmol) was added. The reaction mixture was stirred at rt for 16 hours, then diluted with ELISA (50 mL) and washed with water (10 mL). The organic phase was dried over sodium sulfate, then filtered and concentrated to dryness under vacuum. The obtained substance was purified by FCC (Biotage Isolera, SiO2, gradient elution with 10-50% Â:heptane), followed by chiral preparative SFC LCMS (using a Waters Thar 3100 SFC system connected to a Waters 2998 PDA detector, Chiralcel OJ-H, 10 × 250 mm, 5 μm, eluted at 15 mL / min with 8% acetonitrile:92% CO2) to obtain the marked compound (desired isomer) (5.7 mg). The stereochemistry adjacent to the tetrazole carbon was arbitrarily assigned. A second isomer (undesirable) was also isolated.
number
[0467] Example 16 [ka] N-[(S)-(4,4-difluorocyclohexyl){7-[4,4-difluoro-1-(3-fluorobicyclo[1.1.1]pentan-1-carbonyl)piperidine-2-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide The solution of intermediate 57 (46 mg, 76 μmol) and TFA (1.0 mL) in DCM (1.5 mL) was stirred at rt for 2 hours, and the reaction mixture was then concentrated. The residue was dissolved in MeOH (0.5 mL). The solution was packed into an SCX column and eluted with MeOH, and then with 7N methanolic ammonia. The basic eluent was concentrated. The residue was mixed with 3-fluorobicyclo[1.1.1]pentane-1-carboxylic acid (32.0 mg, 0.25 mmol), HATU (94.0 mg, 0.25 mmol), DIPEA (60 μL, 0.34 mmol), and DMF (1.0 mL). The mixture was stirred at rt for 1 hour, and then concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with a gradient of 0 to 50% HCl in hexane. The resulting yellow solid (30 mg) was separated into diastereomers using an SFC Prep 100 equipped with a Chiralpak IC 150 × 4.6 mm, 3 μm column (flow rate 3 mL / min, runtime 7.5 minutes, eluted with 3-40% methanol (+0.1% ammonia solution)). The labeled compound (first elution peak) (9 mg, 20%) was obtained along with the diastereomer on the opposite side. The absolute stereochemistry at position 2 of the piperidine ring is unknown.
number
[0468] Example 17 [ka] 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[4-(2,2-difluoropropylcarbamoyl)-tetrahydropyran-4-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide Intermediate 69 (50 mg, 0.095 mmol), DIPEA (0.03 mL, 0.2 mmol), and 4-cyclopropyl-1,2,5-oxadiazole-3-carboxylic acid (20 mg, 0.13 mmol) were dissolved in DCM (5 mL), and then HATU (50 mg, 0.13 mmol) was added. The reaction mixture was stirred overnight, then diluted with DCM (10 mL), washed with water (10 mL), passed through hydrophobic frit, and evaporated under vacuum. The residue was dissolved in MeOH, and then purified by basic C18 and preparative HPLC to obtain the marked compound (26 mg, 44%) as a white solid.
number
Claims
1. A compound of formula (I) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 During the ceremony, E represents a group of formula (Ea), (Eb), (Ec), (Ed), or (Ee): 【Chemistry 2】 where the asterisk (*) represents the point of attachment to the remainder of the molecule; A represents a group of formula (Aa), (Ab), (Ac), (Ad), or (Ae): 【Chemistry 3】 where the asterisk (*) represents the point of attachment to the remainder of the molecule; Y is -O-, -N(R 7 ) -, -C(R 5a ) (R 5b )-, -S-, -S(O)-, -S(O) 2 -, or -S(O)(N-R 8 )-represents; Z represents heteroaryl, which may be optionally substituted by one or more substituents; R 1a represents hydrogen, fluoro, chloro, methyl, difluoromethyl, or trifluoromethyl; R 1b represents hydrogen, fluoro, chloro, methyl, difluoromethyl, or trifluoromethyl; R 2 is -OR 2a or R 2 is C 3-9 Cycloalkyl, C 4-12 Bicycloalkyl, C 3-7 Heterocycloalkyl, or C 4-9 any of which may be optionally substituted by one or more substituents; R 2a is C 1-6 represents alkyl; or R 2a is C 3-9 represents cycloalkyl, which may be optionally substituted by one or more substituents; R 3 is -NR 3a R 3b or R 3 represents a group of formula (Wa): 【Chemistry 4】 where the asterisk (*) represents the point of attachment to the remainder of the molecule; W represents the residue of an optionally substituted saturated monocyclic ring containing from 3 to 6 carbon atoms, 1 nitrogen atom, and 0, 1, 2, or 3 additional heteroatoms independently selected from N, O, and S, but containing not more than 1 O or S atom; or W represents the residue of an optionally substituted saturated bicyclic ring system containing from 4 to 10 carbon atoms, one nitrogen atom, and 0, 1, 2, or 3 additional heteroatoms independently selected from N, O, and S, but containing not more than one O or S atom; or W represents the residue of an optionally substituted saturated spirocyclic ring system containing from 5 to 10 carbon atoms, one nitrogen atom, and 0, 1, 2, or 3 additional heteroatoms independently selected from N, O, and S, but containing not more than one O or S atom; R 3a is hydrogen or C 1-6 represents alkyl; R 3b is C 1-6 Alkyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl (C 1-6 ) alkyl, C 4-12 Bicycloalkyl, aryl, aryl (C 1-6 ) alkyl, C 3-7 Heterocycloalkyl, C 3-7 Heterocycloalkyl (C 1-6 ) alkyl, heteroaryl, or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted by one or more substituents; R 4a represents hydrogen, fluoro, or hydroxy; or R 4a is C 1-6 represents an alkyl group, which may be optionally substituted by one or more substituents; R 4b represents hydrogen or fluoro; or R 4b is C 1-6 represents an alkyl group, which may be optionally substituted by one or more substituents; or R 4a and R 4b together with the carbon atom to which they are both attached, 3-9 Cycloalkyl or C 3-7 heterocycloalkyl, any of which may be optionally substituted by one or more substituents; R 5a represents hydrogen, fluoro, methyl, difluoromethyl, or trifluoromethyl; R 5b represents hydrogen, fluoro, methyl, or hydroxy; or R 5a and R 5b taken together with the carbon atom to which they are both attached represent cyclopropyl; R 6 is -OR 6a Or -NR 6b R 6c or R 6 is C 1-6 Alkyl, C 3-9 Cycloalkyl, C 3-9 Cycloalkyl (C 1-6 ) alkyl, aryl, aryl (C 1-6 ) alkyl, C 3-7 Heterocycloalkyl, C 3-7 Heterocycloalkyl-(C 1-6 ) alkyl, heteroaryl, or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted by one or more substituents; R 6a is C 1-6 represents alkyl; or R 6a is C 3-9 Cycloalkyl or C 3-7 heterocycloalkyl, any of which may be optionally substituted by one or more substituents; R 6b is hydrogen or C 1-6 represents alkyl; R 6c is hydrogen or C 1-6 represents alkyl; or R 6b and R 6c taken together with the nitrogen atom to which they are both attached, represent azetidin-1-yl, pyrrolidin-1-yl, oxazolidin-3-yl, isoxazolidin-2-yl, thiazolidin-3-yl, isothiazolidin-2-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homomorpholin-4-yl, or homopiperazin-1-yl, any of which groups may be optionally substituted by one or more substituents; R 7 is -COR 7a , -CO 2 R 7a Or -SO 2 R 7b or R 7 represents hydrogen; or R 7 is C 1-6 Alkyl, C 3-9 Cycloalkyl, or C 3-7 any of these groups may be optionally substituted with one or more fluorine atoms; R 7a is C optionally substituted by one or more fluorine atoms 1-6 represents alkyl; R 7b is C 1-6 represents alkyl; R 8 is C 1-6 Represents alkyl, A compound of formula (I) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof.
2. 2. A compound according to claim 1, wherein E represents a group of formula (Ea) or (Ed) as defined in claim 1.
3. 3. A compound according to claim 1 or 2, wherein A represents a group of formula (Aa), (Ac), (Ad) or (Ae) as defined in claim 1.
4. R 6 4. A compound according to any one of claims 1 to 3, wherein represents heteroaryl, which may be optionally substituted by one or more substituents.
5. The compound according to claim 1, represented by formula (IIA-1) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 5】 During the ceremony, X represents CH or N; R 16 represents methyl, ethyl, isopropyl, or cyclopropyl; A is as defined in claim 1. The compound according to claim 1, represented by formula (IIA-1), or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof.
6. The compound according to claim 1, represented by formula (IIA-2) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 6】 During the ceremony, A is as defined in claim 1, X and R 16 is as defined in claim 5, The compound according to claim 1, represented by formula (IIA-2), or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof.
7. The compound according to claim 1, represented by formula (IIB-1) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 7】 During the ceremony, A is as defined in claim 1, X and R 16 is as defined in claim 5, The compound according to claim 1, represented by formula (IIB-1), or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof.
8. The compound according to claim 1, represented by formula (IIB-2) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 8】 During the ceremony, A is as defined in claim 1, X and R 16 is as defined in claim 5, The compound according to claim 1, represented by formula (IIB-2), or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof. Claim 9: N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-{(S)-(4,4-difluorocyclohexyl)[7-(3,3-difluoro-1-{[(1R)-2-methyl-1-(methylcarbamoyl)-propyl]carbamoyl}propyl)imidazo[1,2-b]pyridazin-2-yl]methyl}-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-{7-[(1R)-1-{[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]carbamoyl}-3,3-difluoro-propyl]imidazo[1,2-b]pyridazin-2-yl}(4,4-difluorocyclohexyl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-{7-[(1S)-1-{[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]carbamoyl}-3,3-difluoro-propyl]imidazo[1,2-b]pyridazin-2-yl}(4,4-difluorocyclohexyl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; 4-cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(2,2,2-trifluoro-ethylcarbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide; 4-cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-(2,2,2-trifluoro-ethylcarbamoyl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethylisoxazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-ethylisoxazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-2-isopropylpyrazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-2-isopropyl-1,2,4-triazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[4,4-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)-cyclohexyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; 4-cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-{[(1S)-2,2,2-trifluoro-1-methylethyl]carbamoyl}propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide; 4-cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-{[(1S)-2,2,2-trifluoro-1-methylethyl]carbamoyl}propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide; N-(2,2-dicyclopropyl-1-{7-[3,3-difluoro-1-(2,2,2-trifluoroethylcarbamoyl)propyl]-imidazo[1,2-b]pyridazin-2-yl}ethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[(1S)-3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]-pyridin-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[(1R)-3,3-difluoro-1-(6-fluoro-[1,2,4]triazolo[4,3-a]-pyridin-3-yl)propyl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[1-(oxetan-3-yl)-4-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidin-3-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[4-(2,2-difluoropropylcarbamoyl)tetrahydropyran-4-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl)(7-{(1S*)-3,3-difluoro-1-[1-(2,2,2-trifluoroethyl)tetrazol-5-yl]propyl}imidazo[1,2-b]pyridazin-2-yl)methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; N-[(S)-(4,4-difluorocyclohexyl){7-[4,4-difluoro-1-(3-fluorobicyclo[1.1.1]pentane-1-carbonyl)piperidin-2-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide; and 4-Cyclopropyl-N-[(S)-(4,4-difluorocyclohexyl){7-[4-(2,2-difluoropropylcarbamoyl)-tetrahydropyran-4-yl]imidazo[1,2-b]pyridazin-2-yl}methyl]-1,2,5-oxadiazole-3-carboxamide 2. The compound of claim 1, which is a compound selected from the group consisting of:
10. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in therapy.
11. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prophylaxis of disorders in which the administration of a modulator of IL-17 function is indicated.
12. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prophylaxis of an inflammatory or autoimmune disorder.
13. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, in association with a pharma- ceutically acceptable carrier.
14. 14. The pharmaceutical composition of claim 13 further comprising an additional pharma- ceutical active ingredient.
15. Use of a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicinal product for the treatment and / or prevention of disorders in which the administration of a modulator of IL-17 function is indicated.
16. 2. Use of a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and / or prophylaxis of an inflammatory or autoimmune disorder.
